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I. INTRODUCTION 
Due to technological innovation, demographic change and the growth of income, 
GDP-proportional health expenditure has regained intense growth in the OECD 
member states after a stagnation that followed the economic crisis of 2008. 
Sustainable financing of healthcare became one of the key challenges of countries 
with developed economies. Decision-makers may need to introduce new decision-
methods in order to maintain equitable and legitim allocation of resources despite the 
growing fiscal pressure. While in the past decades the QALY concept has been 
adopted by an increasing number of countries for the measurement of health outputs, 
its amendment has been suggested both in the measurement of individual well-being 
or in the measurement of societal preferences, for supporting health resource 
allocation decisions. Amending the QALY concept and new ways of measuring health 
outcomes became recently intense areas of research in the field of health economics.  
The research of acceptable health states (AH) started in the Netherlands as well as at 
the Corvinus University of Budapest, approximately 10 years ago. The measurement 
of acceptable health problems applied together with sufficientarian theory – a novel 
theory of justice in the field of health economics – aims to provide a transparent 
picture for decision-makers about the society’s age and disease severity related 
preferences. However, due to the methodological difficulties, indicators have not yet 
been developed, which would make the practical application of the AH concept 
feasible.  
In PhD studies I have been searching for answers to the problems of sustainable 
healthcare financing, especially in the field biosimilars, which represent cost-effective 
alternatives to the expensive biological therapies, as well as in the field of health 
outcomes measurement for economic analysis, the results of which I will introduce in 
later sections of my dissertation.  
In the empirical research detailed in my dissertation, the main goal was to further 
develop the methods that enable the practical use of indicators based on acceptable 
health states. After theoretical planning, the Department of Health Economics 
launched in early 2018 the „Health and Ageing” study, under the leadership of Prof. 
Márta Péntek, during which I had opportunity to test the new measurement methods 
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of acceptable health. In the dissertation I will introduce results of this research in the 
steps detailed below:  
a) In the literature review I introduce the challenges of health financing decision 
making, state-of-the-art methods of resource allocation, the theoretical 
background of acceptable health and the possible areas of its further 
development.  
b) After stating the research goals, I introduce the new methods of measuring 
acceptable health from the theoretical basics through introducing results of my 
research as well as the critical interpretation of the findings.  
c) In the last part of the dissertation I will analyse the association between 
subjective wellbeing (happiness) and acceptable health, and I expand on 
further research areas and practical applicability of acceptable health.  
The main results of my research are the following:  
a) We introduced two new methods of measuring acceptable health. We 
developed an adaptive testing algorithm for the joint measurement of 
acceptable health states, which provides as more accurate and reliable measure 
when compared to previous methods. For measuring acceptable health, we 
used the EQ VAS questionnaire for the first time. Both methods were easy to 
implement in practice.  
b) Using the new methods, we confirmed the results of previous research: people 
accept more health problems with age, and mild problems are considered more 
acceptable than severe ones.  
c) We have demonstrated that acceptable health from the individual’s point of 
view shows similar priorities in terms of age and severity, as from a societal 
perspective.  
d) Backed with data, we pointed out the main areas of developing the acceptable 
health concept further, which are mainly related to increasing the reliability of 
data collection and results.  
The E-matrix obtained through the new measurement method (joint evaluation) of 
acceptable health makes possible the practical application of results, by adapting 
QALY-based health economic models. At the end of the dissertation I introduce 
possibly ways of applying acceptable health measurements in health technology 
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assessment, while relying on sufficientarian and utilitarian as well as egalitarian 
theories of justice.  
As a summary, despite its potential areas for further development detailed in the 
dissertation, acceptable health is a promising new area in the measurement of health 
outcomes, which may open new research avenues on an international scale.  
 
 
Note: terms indicated with asterisk (*) are included the glossary at the end of the 
dissertation in alphabetical order.  
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II. LITERATURE REVIEW 
II.1. Challenges of sustainable healthcare financing 
Sustainable financing is one of the key challenges of OECD countries.  (OECD, 
2015a) Growth of healthcare expenses has surpassed GDP growth over the past 20 
years, and after the temporary diminution due to the 2008 economic crisis, since 2014 
they have been growing at a speed above GDP again. (OECD, 2018) According to the 
European Commission, the definition of sustainable financing is the following: “the 
ability to continue now and in the future current policies (with no changes regarding 
public services and taxation) without causing public debt to rise continuously as a 
share of GDP”. (European Commission, 2014) Sustainable financing does not 
preclude the increase of health expenditure in case it reflects the willingness to pay of 
the society, and it is possible to regroup resources from other budget items. However, 
if the necessary resources are not available, then it may be required to constrain 
otherwise desirable expenditure. (OECD, 2015a) In countries with low to medium 
income, growth of health expenditure was explained by the response to unmet health 
needs and action to provide universal coverage. In countries with high income, 
development of medical technology, demographic shift, increase of salaries and 
anomalies of the health care systems are the key causes of the increasing expenses. 
(OECD, 2015a) The key driver of costs if technological innovation, which, according 
several estimates, makes up as high as 50% of expenditure growth in healthcare. (de 
la Maisonneuve and Martins, 2013, Willeme and Dumont, 2015)  
In addition to radically innovative medical devices, mainly innovative medicines 
contribute to the growth of expenses, which can only partly be balanced by the use of 
so-called generic medicines. (Willeme and Dumont, 2015) In the past few years, 
specialty medicines became the drivers of pharmaceutical expenditure. (OECD, 2018)  
The industrial production of specialized protein medicines enabling targeted 
therapeutic interventions (enzymes, antibodies, hormones, cells) is not based on 
chemical synthesis any more, but happens in living organisms, which we call 
biological therapies. (FDA, 2018) The yearly cost of specialty medicines used for the 
treatment of oncology disorders have surpassed 10000 USD per year by the early 
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2000’s. In 2012, for most of the newly registered oncology therapies, the average 
yearly treatment cost was more than 100000 USD. (OECD, 2015b) Most of these 
specialty medicines are biological molecules. The trends are well illustrated by the 
fact, that the first CAR-T cell therapy, Kymriah® (tisagenlecleucel), which was 
registered in 2017 in the USA for the treatment of childhood leukaemia was 
introduced with a list price of 475000 USD. Owing to its radical efficacy, the product 
was cost-effective. However, the extreme costs are incurred in the first year of therapy, 
while the life-year gains or societal benefits are accumulated subsequently over many 
years.  (Whittington et al., 2018) The proportion of biological therapies among newly 
registered innovative drug molecules is increasing steadily. (Figure 1) In 2018 from 
the 59 new innovative medicines registered in the USA, 17 were biological molecules. 
(Mullard, 2019) From the 10 global top selling drugs in 2017 seven were biologicals, 
all with yearly sales over 5 billion USD. The turnover of biological molecules made 
up 25% of the global pharmaceutical market in 2016 and will reach 30% by 2022. 
(EvaluatePharma, 2017) 
Figure 1 Proportion of biological molecules among newly registered medicines 
 
Source: Adapted from Mullard, FDA* data from 1993 to 2018 (Mullard, 2019) 
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II.2. Interventions for sustainable healthcare financing  
II.2.1. Main areas of intervention for sustainable healthcare financing 
The OECD report from sustainable financing (OECD, 2015a) identified three main 
areas of intervention: (1) reallocation of budget items in favour of health expenses (2) 
increasing the efficiency of public expenditure, (3) re-evaluation of the ratio of public 
and private health expenses. Reallocation of resources is primarily the role of fiscal 
policy.  According to the OECD, increasing the share of private expenditure (either in 
the form of private insurance or increasing the co-pay of services) can result in 
decreasing efficiency of healthcare systems. (OECD, 2015a) In the OECD member 
states, health products (medicines and medical devices) make up the third biggest item 
(19%) among healthcare costs after outpatient care (33%) and hospital care (28%). In 
Hungary, medical products make up the biggest category (32%), and in terms of 
pharmaceutical expenditure (28.8%) Hungary is the second among the OECD 
members states, and first among member states of the European Union. (OECD, 2017) 
The efficiency of public expenditure can be improved mainly be the following 
interventions:  
(a) Containment of pharmaceutical expenditure  
(b) Standardising heterogenous medical practice 
(c) Efficient management of patient-pathways  
(d) Reforming the financing of health-service providers 
(e) Supporting health promotion and prevention programs.  
Pharmaceutical expenses can be curbed by increasing the penetration of generic 
medicines and by efficient procurement practices, while increasing patient co-pay is 
a less efficient intervention with negative consequences on access to care. (OECD, 
2015a)  
II.2.2. The reimbursement policy cycle 
The growth of pharmaceutical expenses and the equilibrium of the pharmaceutical 
budget can be managed by balancing the savings in competitive markets of off-patent 
molecules and the expenses of reimbursing new, innovative patented medicines.  
(Figure 2) Fostering price competition in competitive markets releases resources, 
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which can be used for the reimbursement of innovative molecules with market 
exclusivity. The reimbursement of cost-effective therapies ensures the efficient use of 
the released resources. (Dankó and Molnár, 2013) The examination of the cost-
effectiveness and budget impact of new therapies is the role of health technology 
assessment* (HTA), which will be introduced in chapter II.5. With proper long-term 
planning, the sustainability of reimbursement policies can be ensured. Just as the entry 
of new biological molecules posed a challenge on reimbursement policies and 
practices, the loss of their patent protection also raised new medical and regulatory 
questions, which required the development of new reimbursement policies in order to 
enhance competition in the biological markets. (Gulacsi, 2014) The case studies 
illustration the economic impact of biosimilar medicines will be presented in chapters 
II.2.4. and II.2.5.  
Figure 2 Reimbursement policy cycle 
 
Source: Adapted from p180. Dankó and Molnár (2013), (Dankó and Molnár, 2013) 
II.2.3. The impact of austerity measures on the efficiency of health systems  
The analysis of austerity measures on health expenditure following the 2008 financial 
crisis provided mixed results in terms of healthcare indicators and was not clearly 
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utilisation of healthcare services decreased unambiguously, the long-term effects of 
which are not yet foreseeable. (van Gool and Pearson, 2014) According to the latest 
OECD analysis, widening the range of services that are available in primary care with 
full coverage, as well as decreasing the proportion of co-pay are the two policies that 
contribute most to the improved efficiency of healthcare, while health technology 
assessment, which informs decision-makers about the value and societal effects of 
new health technologies, in parallel with improved health indicators, has contributed 
to growing health expenditures as well. (Lorenzoni et al., 2018) In the future, for 
sustainable financing, increasing selectivity may be warranted during health financing 
decision making, including value-based reimbursement programs supported by health 
technology assessment, and the diminishing of public reimbursement in the case of 
not cost-effective technologies. (OECD, 2015a) In forthcoming decades, in supply-
driven markets, decision-makers managing constrained resources will work under 
increasing financial pressure. (Dankó and Molnár, 2013) 
II.2.4. Case study: the economic effects of biosimilars  
In this chapter, I will briefly introduce the results of my research supporting the 
utilisation of biosimilar medicines. (Pentek et al., 2017, Vezer et al., 2016, Zrubka, 
2017a, Zrubka, 2017b)  
After the patent expiry of traditional, chemical molecules, lower-priced competitors 
containing the same active ingredient are called generic medicines.  (GaBi Online, 
2012) Generic medicines make up 52% in volume and 25% in value the 
pharmaceutical markets of the OECD member states. (OECD, 2017) Biosimilar 
medicines are highly similar to authorised originator* reference biological products 
and introduced to the markets at a lower price. (European Medicines Agency, 2017) 
With the increasing sales of biological molecules, the role of biosimilars in 
moderating pharmaceutical expenses is increasing. However, in the OECD member 
states, the penetration of biosimilars compared to generics shows a much more diverse 
picture. While first-generation biosimilar erythropoietin (a hormone used for the 
treatment of the anaemia in chronic renal insufficiency or oncology disorders) 
(EMEA, 2018) had 68% market penetration in 2015 (highest: 100%, lowest: 2%), the 
second-generation infliximab (a TNF-a inhibitor monoclonal antibody* used for the 
treatment of chronic immune-mediated inflammatory disorders) (EMEA, 2019) 
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reached only 27% market-share. (highest: 82%, lowest: 2%). (OECD, 2017) The 
originator reference brand of infliximab, RemicadeTM was ranking 6-7th on the list of 
top-selling drugs globally between 2012 and 2018.  (PMLive, 2018). Biosimilar 
infliximab was the first biosimilar monoclonal antibody (mAb). Compared to the first-
generation biosimilars, biosimilar mAbs can be characterised by much greater 
molecular complexity and economic significance.  
Despite the ambitious expectations about savings, in most European countries, after 
the launch of biosimilar infliximab, the sales of the molecule continued to increase in 
terms of value, and the utilisation of more expensive originator molecules increased 
at a greater pace compared to the biosimilar products. (Pentek et al., 2017) The market 
penetration below expectation can be explained by multiple factors (Zrubka, 2017a, 
Pentek et al., 2017, Simmons, 2018):  
a) Among the regulations of generic and biosimilar medicines, interchangeability 
has the greatest significance with regards to market competition. (Zrubka, 
2017a) While according to the common European regulations, traditional 
originator and generic medicines are freely substitutable in pharmacies 
without the consent of the prescribing physician – giving way to price 
competition – in case of biological medicines, switching from the originator 
reference product to a biosimilar can happen with the consent of the 
prescribing physician. The interchangeability of biological medicines from 
professional or economic reasons falls under national regulations. (EGA, 
2016) Despite the fact that the development of biosimilar medicines is based 
on the quality controls required after the manufacturing process modifications 
of originator reference products, which has been performed by the European 
Medicinal Agency 404 times before the approval of the first biosimilar mAb,  
(Vezer et al., 2016) due to the lingering concerns about the safety and quality 
of biosimilars, the interchangeability similar to generic medicines was not 
allowed by the financing protocols in many countries, which impeded the 
implementation of effective measures enhancing the uptake of biosimilar 
medicines. (Moorkens et al., 2017)  
b) Savings with biosimilars depended on the choices of prescribing physicians, 
who were neither enforced, nor incentivised for prescribing biosimilars.  
(Moorkens et al., 2017, Zrubka, 2017a) 
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c) Due to the non-transparent agreements between the producers of originator 
reference products and health authorities, the net prices of originator biological 
products were lower than their list prices, therefore the expected price-
advantage of biosimilar was substantially lower compared to the expectations. 
In Hungary, according to the analysis of published patient-data and tender 
agreements of originator products, the price of infliximab and its competitor 
originator brands were procured at prices approximately 50% below the 
official list prices. (Zrubka, 2017a)  
The other barrier of savings with biosimilars (with infliximab in our own research) 
was that due to the high costs of originator molecules, access to TNF-a was very low 
in many countries (Pentek et al., 2014a), therefore, the expectation from the biosimilar 
molecule was improved access, re-investment of the savings into the same therapeutic 
area in order to improve access to therapy. (Brodszky et al., 2014)  
II.2.5. Case study: new therapeutic opportunities with biosimilars 
In the chapter below, I will shortly introduce the published (Zrubka et al., 2018a, 
Gulacsi et al., 2019) as well as submitted (Zrubka et al., 2019c) results of my research 
in the field of the health technology assessment of biosimilar medicines.  
The complex economic effect of biosimilars is illustrated by the fact that these 
molecules can have a role in both sides of the reimbursement cycle. In addition to 
generating savings via price-competition, they may represent cost-effective 
alternatives among the innovative therapies. An example is the timing of the start of 
biological therapy in chronic immune-mediated disorders. In rheumatoid arthritis* (a 
disorder characterised by chronic inflammation of the joints), according to the 
European treatment guidelines, biological therapies are recommended only after the 
treatment failure of conventional anti-rheumatic therapies. (Smolen et al., 2017) 
However, an increasing number of publications have shown that the (even 
intermittent) use biologics  in the earliest phase of the disease may prevent the 
development of a chronic progressive condition (Nagy and van Vollenhoven, 2015, 
van Nies et al., 2014), preventing considerable disease burden for the individual and 
costs for the society. Interestingly, due to the cost-effectiveness arguments, most 
therapeutic guidelines do not support biologics in the earliest phase of the disease. Our 
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systematic literature review and meta-analysis* has shown, that in randomized 
controlled studies immediate TNF-a inhibitor therapy was more efficacious on the 
long-term in the treatment of early rheumatoid arthritis, than strategies applying a 
delayed start of biological treatment. Our meta-analysis has also shown that the 
differences between the results of clinical studies are mainly explained by 
methodological differences, while the efficacy of individual TNF-a molecules do not 
differ from each-other. Re-examination of the evidences about the early use of TNF-
a inhibitors in rheumatoid arthritis may lead to the update of therapeutic guidelines, 
and the more widespread use of biologic therapies. (Gulacsi et al., 2019)  
Our other research projects pinpointed the difficulties of synthesising the evidence 
available for biological therapies, and therefore highlighted the challenges of making 
evidence-based health financing decisions.  In case of infliximab, studies examining 
the effect of first-line biological therapy in early rheumatoid arthritis published results 
in 200 different combinations of outcomes and time-points. Out of these we found in 
only 17 cases (8.5%) two identical end-points, which enabled the synthesis of the 
available evidence. (Zrubka et al., 2018a). The studies examining the cost-
effectiveness of first-line infliximab therapy in early rheumatoid arthritis were 
performed using the originator reference infliximab. The therapeutic guidelines 
published after the market entry of biosimilar infliximab referred to the unfavourable 
cost-effectiveness first-line biological therapy despite that cost-effectiveness studies 
were not performed with biosimilars priced at considerably lower levels compared to 
the originator molecules. (Zrubka et al., 2019c) The cost-effectiveness analysis of 
early biological therapy in rheumatoid arthritis is part of the ongoing research at the 
Department of Health Economics of the Corvinus University of Budapest. The 
example of infliximab illustrates, that although in the future the popularity and 
utilisation of biosimilars will increase, due to the deficiencies of the available 
evidence and regulations, biosimilars will probably not be able to fully offset the 
growth of expenses generated by newly registered innovative biological molecules 
entering the market.  
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II.3. Ethical decision-making under constrained resources  
The allocation of scarce resources (rationing) is a subject of several theories of 
justice*, grounded in various ethical political or philosophical backgrounds. The 
levels of allocation, as well as the means of implementation are diverse, as the 
opinions about the topic. (Tanyi and Kollányi, 2008) The views that reject the 
restriction of provision of health services due to economic reasons are not acceptable 
neither on ethical, nor economic grounds. (Tanyi and Kollányi, 2008) Designing an 
efficient health service package (and thereby allocation of scarce resources based on 
economic arguments) is one of the main pillars of universal health coverage, 
according to the WHO. (WHO, 2010) Williams argued that cost-effectiveness analysis 
is ethical, since all costs are associated with consequences, and therefore they have 
negative implications on the bearers. Therefore, ignoring costs during any decision 
can be regarded as unethical practice. He also points out that every decision is made 
by hidden priorities, and the benefit of systematic cost-effectiveness analysis is 
derived exactly from revealing those hidden preferences so that the most appropriate 
ethical stance for the given context can be deliberately chosen. (Williams, 1992) 
Norman Daniels and James Sabin (Daniels and Sabin, 2008, Daniels, 2000) see 
fairness and legitimacy of resource allocation decisions in the nature of the process 
leading to the decisions, and not in the applied principles of justice per se. According 
to the theory of „accountability for reasonableness” the characteristics of a fair and 
legitimate process are the following:   
a) Transparency: the principles serving as the basis for decisions need to be 
transparent.  
b) Relevance: decisions have to be made by principles which are acceptable for 
all stakeholders of the decisions 
c) Revision: there must be a mechanism, which allows the revision of past 
decisions on the grounds of new evidences, and settle disputes 
d) Enforcement: there must be a process that guarantees the implementation of 
the above three elements.  
The authors stress that decisions must follow one of the general theories of justice and 
they should not be discriminative.   
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II.4. Theories of fair allocation of health resources 
Theories of justice differ from each other in whether they are concerned primarily 
with the fair allocation of health, healthcare resources, access or the satisfaction of 
needs. (Culyer and Wagstaff, 1993) Health cannot be redistributed, and health is 
affected by several societal factors. Therefore, practically applicable principles rather 
concentrate on the fair distribution of the societal determinants of health, as there is 
no consistent theory, which would guide the fair allocation of health. (Tanyi and 
Kollányi, 2008, Gulácsi, 2012) The following theories are concerned with the fair 
allocation of health resources:  
b) Utilitarianism* focuses on maximising individual utilities, its practical 
implementation is based on cost-effectiveness analysis. (Tanyi and Kollányi, 
2008) 
c) Communitarianism* focuses on the principles of deliberative democracy, in 
which individuals choose the health programs according to their own 
preferences, and collectively define its structure, rules, principles of 
distribution etc. (Tanyi and Kollányi, 2008)  
d) Egalitarianism* is the most frequently cited theory of justice, with many 
interpretations, but the most common starting point is that people are morally 
equal, therefore their life chances cannot be determined by morally arbitrary 
factors (Tanyi and Kollányi, 2008) The following theories can be linked to 
egalitarian principles:  
o The needs-based approach states that people with equal needs need to 
be treated equally. (Gulácsi, 2012)  
o Equal access suggests equal chance for the access to services, 
irrespective of their results. (Gulácsi, 2012) 
o Minimum essential health coverage in each disease, defined via wide 
societal consensus. (Gulácsi, 2012) 
o The fair innings* principle suggests that everyone is entitled a fair 
length of life (e.g. 70-75 years), and we need to provide equal chances 
for people to reach it. (Gulácsi, 2012) 
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e) Prioritanism is the critique of the equal needs principle and suggests that 
people in more severe conditions should receive greater priority. (Parfit, 1995, 
Nord et al., 1999) 
f) Libertarianism is the least commonly cited principle, which derives its 
healthcare model from the autonomy of the individual and the refusal of 
external authority. (Gulácsi, 2012) 
g) Sufficientarianism is a new theory of justice, according to which it is not the 
equal distribution of goods that matter, but that everyone should have enough. 
(Gosseries, 2011, Wouters et al., 2017) Sufficientarianism can be further 
divided to a positive and a negative thesis (Casal, 2007):  
o Positive thesis: it is morally important that individuals live above the 
sufficientarian threshold.  
o Negative thesis: no other theories of justice (especially egalitarianism 
and prioritarianism) are morally irrelevant.  
When interpreting theories of justice, it is important to emphasize, that 
parallelly with their development, technological innovation has shaped the 
relationship between the demand and supply of health services.  At the 
establishment of the British National Health Service in 1948, regardless of age, 
gender, religion, place of living or societal class, provision of the same health 
services was the guiding principle, which is driven by the individuals’ needs 
and not their ability to pay.  This principle was soon replaced by the problem 
of the distribution of scarce resources (rationing).   (Crisp, 2002) All theories 
of justice have elements that can be criticised from an alternative viewpoint, 
and most of them contradict the principle of maximum cost-effectiveness. The 
Oxfordshire Health Authority applies the accountability of reasonableness 
principle in practice, during which cost-effectiveness is evaluated initially, 
followed by a multiple-step deliberative process, gradually evaluating 
additional criteria of justice, and eventually decisions are made about the need 
extent to which cost-effectiveness principles are overridden. (Hope et al., 
2002) 
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II.5. Health Technology Assessment (HTA) 
According to the definition of the European Network for Health Technology 
Assessment (EUnetHTA) HTA “is a multidisciplinary process that summarises 
information about the medical, social, economic and ethical issues related to the use of a 
health technology in a systematic, transparent, unbiased, robust manner. Its aim is to inform 
the formulation of safe, effective, health policies that are patient focused and seek to achieve 
best value.” (EUnetHTA, 2007) The recommended modules of HTA by EUnetHTA 
are the following (EUnetHTA):  
a) Relative effectiveness assessment 
o Current use of the technology 
o Technical specifications 
o Safety 
o Clinical efficacy 
b) Local (national) assessment 
o Costs and economic evaluation  
o Ethical evaluation 
o Organisational effects 
o Patient/ and society-level effects, legal implications  
Health economic evaluation involves most frequently cost-utility or budget impact 
analysis. Both methods compare the new technology with the usually applied standard 
care. Cost-utility analysis* (CUA) matches health outcomes measured in quality 
adjusted life years* (QALYs) with costs, while budget impact analysis* (BIA) 
analyses the financial effects of introducing a new technology on the healthcare 
system. (Gulácsi, 2012) 
II.6. Multiple criteria decision analysis (MCDA) in healthcare 
Due to the multitude of sometimes conflicting distributional principles and the 
complexity of the information affecting decisions, health financing decision making 
is a complex, mentally demanding process, in which, without rational decision-
analytical techniques, ad-hoc decisions may result in system-level flaws. (Baltussen 
and Niessen, 2006) The structure provided by Multiple-Criteria Decision Analysis 
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(MCDA) can provide the transparency required by the accountability of 
reasonableness principle. (Thokala et al., 2016) MCDA can be used in many layers of 
health decision making but compared to the complexity of the decisions being taken, 
it is a rarely used methodology. MCDA techniques can be manifold depending on the 
decision, available data and the underlying theories. According to their two main 
definitions, we differentiate techniques which aggregate multiple criteria in a single 
metric, (Keeney and Raiffa, 1993) or techniques which enable deliberation without 
aggregating the results (Belton and Stewart, 2002). The International Society of 
Pharmacoeconomics and Outcomes Research (ISPOR) has issued its guidelines for 
applying MCDA in evaluation of the value of health technologies. The main steps of 
the process are the following:   
(f) Defining the problem: defining the goals, type of problem, alternatives, 
stakeholders and types of expected outcomes 
(g) Criteria: choosing relevant criteria for the evaluation of the alternatives  
(h) Evaluation of performance: gathering data based on the selected criteria and 
creation of a performance-matrix 
(i) Scoring: within each criterion, determining the levels of performance 
(j) Weighting: determining the relative importance of individual criteria 
(k) Aggregation: based on the performance rating of alternatives, ranking 
alternatives based on their aggregated results 
(l) Sensitivity analysis: evaluating the robustness of results.  
(m) Interpretation of results and reporting 
In the 35 English-language publications about MCDA between 2005 – 2015, 93% 
contained criteria regarding the technology, and 81.8% contained criteria regarding 
patient-centric aspects as well as budget impact, which highlights the importance of 
integrating economic aspects with other quality-related criteria in a transparent 
manner. (Kim et al., 2017)  
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II.7. Measuring health outcomes using quality adjusted life years (QALYs) 
II.7.1. Introduction to the QALY concept 
The QALY is the most frequently used measure of health outcomes in health 
economic analyses in countries with developed economies. (Rios-Diaz et al., 2016) 
The QALY expresses the length of life and the quality of life in a single measure, 
where 1 denotes full health, while death is denoted by 0. Health states worse than 
death are indicated by negative numbers. The QALY does not differentiate between 
the length or quality of life, the severity of conditions or the individuals. A year in full 
health is considered equal to ten years spend in 0.1 quality of life, and the 
improvement of the health from 0.2 to 0.4 in a 30-year-old person is equal to the 
improvement from 0.8 to 1.0 at the age of 60 (Gulácsi, 2012).  
The utility values of each health state are determined by measuring the preferences of 
the general population. It is still a matter of active debate, whether utilities should be 
derived from the normal population or affected patients, and whether the evaluated 
health states should be imagined, or actually experienced by respondents (Brazier et 
al., 2018). According to one reasoning, patients can provide more accurate 
information abouth the health states they experience, and they are the stakeholders of 
the decisions. According to the other reasoning, members of the general population 
can evaluate conditions impartially, and they are the bearers of the costs of care. 
Patients usually adjust to their health states, and therefore they evaluate the imagined 
health states as less severe, compared healthy individuals. HTA authorities in most 
countries rely on utilities derived from the normal population evaluating imagined 
health states, but interestingly the Swedish authority prefers, and some countries 
accept health economic evaluations using utilities derived from patients. (Brazier et 
al., 2018) Health-related utilities can be determined via direct and indirect methods. 
Direct methods use valuate concrete disease-descriptions, while indirect methods 
render utilities to health states described by generic quality of life instruments. The 
common feature of both methods is that they evaluate the utility of discrete health 
states (Brazier et al., 2019).  
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II.7.2. The EQ-5D questionnaire 
In health-economic analyses the EQ-5D* is the most frequently applied generic 
quality of life instrument (Brazier et al., 2019). The so-called EQ-5D-3L version 
measures 3 levels of health problems (1: no, 2: moderate, 3: severe) in five health 
dimensions (mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression), thereby describing 243 (35) discrete health states. We denote 
health states by a five-digit number constructed from the problem levels in each 
dimension, called and EQ-5D-3L profile*. For example, the 21121 profile indicates a 
health state characterised by moderate problems in the mobility and pain/discomfort 
dimensions (EuroQoL Group, 1990). There is version using five problem-levels, and 
thereby describing 3125 (55) distinct health states (EQ-5D-5L) (Herdman et al., 2011), 
however, this dissertation focuses on the EQ-5D-3L questionnaire and the term EQ-
5D will refer to the EQ-5D-3L instrument. The sum of the problems levels in each 
dimension are called the „misery index”  (Augustovski et al., 2013), which can be 
used to estimate the severity of problems, but it is not adequate measure for 
determining QALYs. In case of the EQ-5D-3L instrument, the misery index can take 
values between 5 (1+1+1+1+1) and 15 (3+3+3+3+3). The EQ VAS* thermometer is 
also part of the EQ-5D instrument, which records the current health status of 
respondents between the imaginable worst and best (0-100) health states. Utilities can 
be rendered to the discrete EQ-5D health states by using the standard gamble (SG)*, 
time trade-off (TTO)*, rating scale (VAS)*, or recently the discrete-choice 
experiment (DCE)* methods. The common feature of all techniques is that the 
valuation is performed only on a selected health states (frequently based on 
considerations not necessarily optimal for econometric evaluation) (Yang et al., 
2018). The displayed health states contain combinations of different levels of 
problems in the five dimensions, which are evaluated jointly by the individuals. The 
full value-set is determined using econometric models.  
II.7.3. Valuation of health states 
The methods of health valuation are the following:  
a) SG: subjects need to choose from two situations: A) he/she stays in the 
displayed health state until the end of his/her life, B) due to a therapy, with p 
probability he/she returns to perfect health, or with 1-p probability he/she dies 
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immediately. The utility of the health state is calculated from the p value where 
the individual becomes neutral between the two alternatives. (Gulácsi, 2012) 
b) TTO: the subject needs to choose from two alternatives: A) he/she stays in the 
displayed hypothetical health state for x years. B) he/she gets perfect health 
for t years and dies immediately thereafter. The utility can be calculated from 
the t value, where the individual becomes neutral between the two alternatives. 
(Gulácsi, 2012) 
c) DCE: subjects need to choose between two alternatives: A) he/she spends x 
time in health state „A” or B) he/she spends y time in health state „B”. The 
combination of problems and the length of time periods always requires 
evaluation, there is no straightforward choice. The utility can be derived using 
multivariate (e.g. multinomial logit) regression (Bansback et al., 2012, Baji, 
2012, Hauber et al., 2016). 
d) VAS: the subject marks the place of death on the health thermometer between 
the best and worst imaginable health states. Then he/she marks several 
predefined health states. The utility is derived from the relative place of health 
states between full health (100) and death (0) (Gulácsi, 2012, Brooks et al., 
2003). 
The utilities rendered to each EQ-5D profile are called EQ-5D index values. In 
different countries the index values determined with specific valuation methods are 
called value sets*. For instance, the EQ-5D-3L index values of health states 11111, 
21121 and 33333 using the United Kingdom’s TTO value set (UK-TTO) are 1, 0.727 
and -0.594, respectively (Dolan, 1997). 
The theoretical background of measuring health-related utilities is rooted in the Von-
Neumann-Morgenstern expected utility theory (Von Neumann and Morgenstern, 
1944). With the exception of the VAS rating scale, valuation methods involve a 
hypothetical choice situation, an exchange involving sacrifice and different levels of 
uncertainty. However, due to the different cognitive evaluation tasks, the valuation 
results of the different methods are also different. (Bleichrodt and Johannesson, 1997, 
Bansback et al., 2012) Furthermore, several studies have demonstrated that during the 
evaluation of utilities, respondents diverged from perfectly rational choices, according 
to patterns predictable by Kahneman and Tversky’s prospect theory (Bleichrodt and 
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Johannesson, 1997, Kahnemann and Tversky, 1979).  Utility measurements are 
influenced by the following systematic distortions (van Osch et al., 2004):  
a) Time preference: people value more recent health gains as more valuable than 
distant ones in time. This results the under-valuation of utility values in TTO 
exercises.  
b) Estimation of probability: people overestimate the likelihood of events with 
low probability (<0.33) and undervalue the likelihood of events with high 
probability (>0.33). This results in the overestimation of utilities in SG 
experiments.  
c) Loss-aversion: people are more sensitive to losses than to gains, therefore both 
TTO and SG result in over-valuation of health states.  
d) Measurement scale effect: the interaction of the instrument and the responses 
have been described for both SG, TTO and VAA (Parkin and Devlin, 2006, 
van Osch et al., 2004, Matejka et al., 2016).  
II.7.4. Critical analysis of the QALY concept 
In the following chapter I will briefly refer to the results of my research conducted 
with the EQ-5D and CarerQoL questionnaires, which complement the QALY concept 
or focus on its measurement properties (Zrubka, 2017b, Zrubka et al., 2019a, Baji et 
al., 2019, Zrubka et al., 2019b). 
From systematic distortions of the valuation methods we can conclude that health 
related utilities cannot be viewed as time-independent linear concepts, while we apply 
this assumption during health economic analyses.  
The inaccuracies of models based on QALY maximisation are not explained only by 
the systematic distortions of the valuation methods, but also by their differences from 
societal priorities about health gains*. After reviewing 64 empirical studies, Dolan 
and colleagues have identified the following typical societal preferences (Dolan et al., 
2005):  
a) People give priority to treating more severe patients  
b) People give priority to young people (especially young adults) over older 
individuals 
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c) People would attach negative priorities to those who are (may be (own 
remark)) considered responsible for their health problems.  
d) People would give priority to those who bear responsibility for others (e.g. 
parents of small children) 
e) People prefer to balance societal inequalities 
The most typical pattern in the terms of time and quality of life is the diminishing 
marginal utility: the societal preferences to treat healthier and older individuals tend 
to be lower. (Dolan et al., 2005) Furthermore, threshold-dependent changes of health 
preferences were also observed in some studies: individuals would distribute equally 
health gains that are greater than a certain threshold. It this threshold is not achievable, 
then people would focus the resources on a smaller group of individuals in need 
(Olsen, 2000).  
A further critique of the QALY model is that certain variables that are important for 
the health or wellbeing of the individual are not measured sensitively enough or not 
measured at all by generic quality of life instruments. The most important elements 
that are missing from the current QALY model are the following (Brazier et al., 2019):  
a) Health dimensions: sleep, vision, hearing, cognition 
b) Dimensions of social and subjective wellbeing: autonomy, social 
relationships, feeling in control, positive affect 
c) The quality of life of informal caregivers 
Most dimensions that are missing from the QALY model have validated measures, 
but the value sets required for health economic analyses have not been determined, 
with some exceptions:  
a) ICECAP: this measure of wellbeing is based on Amartya Sen’s capability 
approach, which was developed to measure the effect of health and social care 
interventions. The questionnaire measures full-capabilities / lack of 
capabilities along several dimensions, and the value set has been determined 
by best-worst scaling method. ICECAP has adapted versions for several 
situations (adults, older individuals, individuals with terminal illness, 
caregivers) (Al-Janabi et al., 2012, Flynn et al., 2015)  
b) CES (Caregiver Experience Scale): member of the ICECAP „family”, this 
instrument measures the quality of life of informal caregivers. Its valuation 
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was performed using the best-worst scaling method, based on the preferences 
of caregivers of elderly patients (Al-Janabi et al., 2011).  
c) CarerQoL measures the quality of life (both positive and negative experiences) 
of informal caregivers in a similar format to the EQ-5D. The developers 
rendered a happiness-based value set to CarerQoL reflecting the preferences 
of the normal population. The value set has been determined in several 
countries (Brouwer et al., 2006, Hoefman et al., 2017). The Hungarian 
adaptation of CarerQoL is already ongoing at the Department of Health 
Economics of the Corvinus University of Budapest (Zrubka, 2017b, Baji et al., 
2019).  
Overall, models that maximise QALYs do not provide a solution for the optimal 
allocation of scarce resources, neither from a utilitarian, nor from an egalitarian point 
of view, which explains, why it is so important to consider other qualitative 
perspectives in addition to results of cost-effectiveness analyses during health 
resource allocation decision making. However, the EQ-5D based QALY concept is 
supported by the deep knowledge about the measurement properties of the instrument 
due to very thorough psychometric validation. Furthermore, due to the widespread use 
of the instrument, data allowing the standard comparison of the broadest range of 
interventions are available (Brazier et al., 2019). However, comparative studies do not 
solve the problem of measurement biases. In our own research, we compared the EQ-
5D value sets of four countries for 18 diseases. The results pointed out the differences 
of the value sets that arise from different valuation methodologies. During the 
pairwise comparisons of disease burden (the difference between the utilities of 
patients and those of the age and gender-matched normal population) between all 
diagnoses,  change of the value set changed the priority order of diseases in 23% of 
the cases (Zrubka et al., 2019a, Zrubka et al., 2019b). Measuring QALYs and the 
application of EQ-5D is an area under continuous methodological development, and 
financing decisions based exclusively on QALY-based calculations can be just as 
flawed as the ones, which ignore the health-economic evidences obtained through the 
use of currently available instruments.  
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II.8. Measuring acceptable health states (AH) 
Theories of justice concerning the fair allocation of health resources consider perfect 
health as the point of reference, where health losses or gains are compared to perfect 
health with utility 1. The concept of acceptable health states (AH) is based on the 
assumption that certain health problems are taken by people as a natural consequence 
of aging, which is worthwhile taking into consideration during the allocation of scarce 
health resources, and use them as a reference-point instead of perfect health (Wouters 
et al., 2017). Empirical studies have shown that people consider more health problems 
acceptable with age.  (Brouwer et al., 2005, Pentek et al., 2014b, Wouters et al., 2015)  
The measurement of acceptable health is based on the prospect theory of Kahneman 
and Tversky, according to which people evaluate gains and losses compared to an 
internal reference point. In turn, the reference point is influenced by the options and 
the expectations of individuals (Kahnemann and Tversky, 1979). A loss below the 
reference point (not acceptable health state) is more important for people, than the 
gain above the reference point (better than acceptable health). According to the AH 
concept, not acceptable health states would receive greater, while acceptable health 
states would receive smaller priorities during decision making, so the willingness to 
pay of the society would be greater for health gains below the acceptability threshold 
than for ones above (Wouters et al., 2017). 
The measurement of AH is a new field, apart from my research, so far three studies 
were concerned with the measurement of AH. All three studies have confirmed that 
there is an internal reference point, according to which people evaluate the 
acceptability of health states in different ages (Brouwer et al., 2005, Pentek et al., 
2014b, Wouters et al., 2015). It was a common feature of all three studies that the 
acceptability of health states was measured using the EQ-5D instrument, which is 
applied for QALY calculations as well.  
The first study was conducted by Brouwer et al. at the Erasmus University Rotterdam 
by interviewing 226 individuals between 18-65 years of age from the Dutch general 
population (Brouwer et al., 2005). The key questions of the study were:  
a) Are certain non-perfect health states acceptable as age advances?  
b) Is the acceptability of problems different in certain health dimensions?  
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The question was asked separately for each EQ-5D dimension, according to the 
following wording: „please indicate with X,  
The question was asked by each dimension separately, according to the following 
wording: „Can you indicate beyond what age do you consider the specified level of 
problems with ‘mobility’ to be acceptable?” The version of this question used in our 
research is shown in Figure 3). Age groups were asked between 30 and 80 years in 
10-year intervals. Participants were instructed to imagine perfect health in other 
situations. In addition to EQ-5D dimensions, questions relating to sexual activity and 
fertility were asked as well. The results confirmed that the acceptability of problems 
was different by dimensions and increased with age. The level of acceptable health 
was somewhat rated lower by respondents than the health status of the normal 
population for each age group. Moderate problems were more frequently acceptable 
than severe ones, and problems were least frequently acceptable in the anxiety / 
depression dimension. As a weakness of the research, the authors noted that the 
evaluation of the acceptability of problems happened by dimension, separately, while 
in reality problems happen in combination, and their joint evaluation would probably 
influence their acceptability. Their other question was whether people mean the same 
problems under the same problem levels in different ages? If a young or older 
respondent evaluates the same objective functional state with different severity labels 
in different ages, that may influence the assessment of acceptability (Brouwer et al., 
2005). 
Figure 3 Separate evaluation of acceptable health problems 
 
The question used in our research during the separate evaluation of the acceptability of health states 
 
The second study was conducted by Péntek et al. in Hungary on 77 patients with 
rheumatoid arthritis starting biological therapy. (Pentek et al., 2014b) The research 
 - 36 - 
objective and methods were similar to the Dutch study, but in addition to EQ-5D, 
acceptable health states were measured using the HAQ-DI disease-specific quality of 
life instrument (Maska et al., 2011).  The study confirmed in both the EQ-5D and 
HAQ-DI dimensions that chronic patients consider more problems acceptable with 
age, and the level of acceptable problems increases with age. Severe problems were 
less acceptable than moderate ones, and patients considered problems with usual 
activities the least acceptable. Patients rated level of acceptable health above 60 years 
of age as lower than that of the normal population, while higher than their own health 
status. Among the limitations of the study the small sample size, the lack of a validated 
instrument for the measurement of acceptable health, and the problem, which was 
already pinpointed by Brouwer et al: the evaluation of acceptable health states 
happened separately by dimensions and joint jointly (Pentek et al., 2014b).  
The third study was also conducted by the Erasmus University Rotterdam team 
(Wouters et al., 2015). Data were collected from a representative online sample of 
1067 individuals in the Netherlands. The goals of the research were the following:  
a) Reinforcing the concept of AH: are less-than-perfect health states acceptable 
and does their acceptability depend on age?  
b) From acceptable health states and acceptable length of life constructing a 
„measure of acceptable health”, which, similarly to the fair innings concept, 
would measure a fair lifetime amount of acceptable health.  
c) Analysis of the association of acceptable health with socio-demographic 
variables and health related experiences.  
Acceptable health was measured in three ways:  
a) Separate evaluation: in each EQ-5D dimension, from what age the different 
levels of problems are acceptable? (Between 40 and 90 years, in 10-year 
intervals).  
b) Joint evaluation: what are the ages, from which the below mentioned three 
EQ-5D health profiles (21211, 22221, 33312) are acceptable?  
c) Acceptable length of life: from what age is death acceptable?  
Subjects of the separate evaluation did not receive further instructions regarding how 
to imagine the health problems in each dimension: a) with full health in other 
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dimensions, b) in combination with other problems. For summarizing their results, the 
authors constructed the following measures of AH:  
a) Aggregate Acceptable Health Curve (AHCaggregate): the main assumption is that 
the health state aggregated from the problems that are acceptable separately in 
each dimension would also be acceptable by the respondent. The sample’s 
AHCaggregate is constructed from the mean EQ-5D-3L index values of the 
individual AHCaggregate health states.  
b) Worst Acceptable Health Curve (AHCworst): the main assumption is that 
problems in each EQ-5D-3L dimension are acceptable only in the presence of 
perfect health in other dimensions. Since health problems in several 
dimensions may be indicated as acceptable in a certain age, the sample’s 
AHCworst is constructed from the lowest individual AHCworst values in each 
age.   
c) Profiles’ Acceptable Health Curve (AHCprofiles): the mean age from which EQ-
5D-3L profiles are considered acceptable by the sample is plotted against their 
EQ-5D-3L index values.  
The three acceptable health curves (AHCaggregate, AHCworst, AHCprofiles) are depicted in 
Figure 4. Main findings of the study were the following:  
a) The concept of AH was reinforced: people consider more non-perfect health 
states acceptable with age. Similarly to the previous Dutch study, severe 
problems are less acceptable as moderate ones, and problems were least 
acceptable in the anxiety / depression dimension.  
b) Age, health status, lifestyle and experiences concerning health influence the 
amount of acceptable health. Older respondents and ones who had chronic or 
severe disease considered more health problems acceptable. People following 
a healthy diet considered less problems acceptable. The lifespan of the closest 
relative also influenced the amount of acceptable health.  
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Figure 4 Acceptable health curves 
 
Source: (Wouters et al., 2015) We used the figure with permission from the authors under the Creative 
Commons 4.0 (CC BY 4.0) agreement. The vertical axis indicates quality of life measured by the EQ-
5D-3L index values. Aggregate Acceptable Health Curve, (AHCaggregate): mean index values of health 
states aggregated from all acceptable health problems in the five dimensions. Worst Acceptable Health 
Curve, (AHCworst): mean of the lowest index values of acceptable health states constructed from isolated 
health problems in each dimension assuming full health in others. Profiles’ Acceptable Health Curve, 
(AHCprofiles): constructed from the index values of the jointly evaluated health profiles and the mean 
age from which they were considered acceptable  
The limitation of the study was the following:  
a) There were no respondents above 65 years of age, therefore the preferences of 
the elderly population could not be analysed.  
b) AH was measured via separate evaluation. The three AHCs showed 
inconsistent picture. While the difference was rather big between the levels of 
AHCaggregate and AHCworst in older age groups, the jointly evaluated AHCprofiles 
crossed the curves gained with separate evaluation. (When evaluated jointly, 
moderate states were acceptable in older ages, while more severe states in 
younger ages, than expected from the results of separate evaluation.) Finding 
the exact location of the acceptable health curve was not successful, and the 
authors proposed the joint testing of more EQ-5D profiles as a future research 
field in order to improve the accuracy of measurement.   
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c) Acceptable health was not defined exactly: therefore, it could be interpreted in 
multiple ways by respondents (it is the health state still enough for wellbeing, 
or the still tolerable level of suffering?) 
d) The reference person was not defined: respondents could evaluate acceptable 
health referring to themselves or others as well.  
The authors noted, that the normative framework of applying AH in health financing 
decision making has not yet been established, therefore they could just conceptually 
illustrate the application of AH.  
II.9. The normative framework for using AH in financial decision making  
Based on sufficientarian reasoning, Wouters et al. examined a possible normative 
framework for applying AH in financial decision making (Wouters et al., 2017). Their 
main conclusions were the following: 
a) Deterioration of health with age is a natural phenomenon, it affects everyone, 
therefore AH may be a feasible reference point for health financing priority 
setting.  
b) The concept of AH fits the sufficientarian principle, insofar as it does not aim 
to either achieve perfect health or equality of health. Its aim is that everyone 
gets into acceptable health.  
c) The positive thesis of sufficientarian reasoning is also acceptable: it is morally 
important to live above the acceptability threshold. If individuals who are not 
acceptable health receive greater, while ones in acceptable health receive 
lower priorities, that can be in harmony with the prioritarian principle, the fair 
innings principle and also with preferences of the general population. The 
negative thesis (the invalidity of other theories of justice) is not acceptable.  
d) The financing importance weight (w) rendered to the health gains can be 
defined with several versions of the AH-based value-function (w=f(U)), where 
KE denotes the starting health state in acceptable health, KN denotes a not 
acceptable starting health state, EE denotes an acceptable health state as 
outcome, EN denotes a not acceptable health state as outcome. U is the utility 
of health states, TE is the acceptability threshold, and c1, c2, p1, p2 and q are 
arbitrary parameters, where 0<c1,c2, p1, p2, q<1. 
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o Sufficientarian base value function (Figure 5.a): 
 	"($) = '1, *"	$ ≤ 	,-0, *"	$ > ,-	* 
o Strict sufficientarian value function (Figure 5.b):  
 f(U) = 20, if	K5 ∧ E5																																															1, if	K5 ∧ E5 ∧ U ≤ T9																													0, if	(K5 ∧ E5 ∧ U > T9) 	∨ (K9 ∧ E9)	 
o Modest sufficientarian value function (Figure 5.c):  
f(U) = 2q, if	K5 ∧ E5																																															1, if	K5 ∧ E5 ∧ U ≤ T9																													0, if	(K5 ∧ E5 ∧ U > T9) 	∨ (K9 ∧ E9)	 
o Sufficientarian and prioritarian hybrid value function (Figure 5.d):  
"($) = < => − @>$, *"	AB ∧ CB																																																																																					D, *"	AB ∧ CB ∧ $ ≤ ,-;FℎHIH	D < 		 => − @>$																																									=K − @K$, *"	(AB ∧ CB ∧ $ > ,-) 	∨ (A- ∧ C-);	−@K$ < 		 => − @>$  
 
e) The principle of AH is acceptable morally if there is considerable difference 
between the utilities of acceptable and not acceptable health states. However, 
the precise measurement of the AH threshold has not been feasible so far. 
Therefore, the authors suggested a soft application of the AH concept: in 
combination with other theories of justice, they consider the application of 
rounded utility functions feasible instead of using ones with sharp threshold 
values.  
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Figure 5 Value functions based on the principle of acceptable health (AH) 
 
Source: adapted from (Wouters et al., 2017). The horizontal axis depicts the utility of health states, 
while the vertical axis shows the financing priority weights (min 0, max 1) attached to the starting (K) 
and outcome (E) health states during the technology assessment of a technology. A health gain is 
illustrated by a move on the horizontal axis from left to right. Health states left from the acceptability 
threshold are not acceptable, while ones on the right are acceptable. KN denotes a not acceptable 
starting health state, EE denotes an acceptable health state as outcome, EN denotes a not acceptable 
health state as outcome. A) Sufficientarian base function: the priority weight (w) of health states in not 
acceptable health is 1, while in acceptable health states is 0. B) Strict sufficientarian value function: 
the priority weight of health gains in not acceptable health states is 1, while health gains in acceptable 
health, or health gains that do not take the individual to acceptable health have priority weight 0. C) 
Modest sufficientarian value function: in not acceptable health states the priority weight falls between 
0 and 1, the weight of health gains in acceptable health states is 0, and the weight of health gains 
leading from not acceptable health states to the acceptability threshold is 1. D) Sufficientarian and 
prioritarian hybrid value function: the priority weight of severe health states is greater than that of 
milder health states, the weight of health gains from non-acceptable health states until the acceptability 
threshold is 1.  
 
Wouters et al. (Wouters et al., 2017) proposed the following areas of research for the 
future development of the AH concept:  
a) Embedding the AH concept in the normative framework of alternative theories 
of justice 
b) Developing reliable methods of measurement 
c) Adapting the AH concept to health outcomes other than QALYs 
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d) Developing AH framework for interpreting health losses, 
e) Determine the interrelationship between AH and time 
II.10.  Avenues for the further development of the AH concept 
The pressure from technological innovation in healthcare requires the fair and 
effective harmonisation of societal priorities and economic constraints in healthcare 
decision making. Prioritanism and the fair innings principle are the two widely 
accepted societal priorities, which could be considered during priority setting in 
healthcare financing. However, these two principles do not provide answers about 
what weight the decision maker should attach to each of them during their 
simultaneous application. Which should receive higher priority from a mild condition 
in a young individual or a severe one in an older patient? The benefit of the AH 
principle is that it unites people’s preferences about the severity of disease and age – 
since the acceptability of a health state is defined simultaneously by both its severity 
and the age of the individual in question. Despite its merits, the QALY-based 
measurement of health outcomes can be criticised from multiple grounds, therefore it 
is necessary to consider further aspects for the sake of effective decision-making. The 
benefit of the AH concept is that it is based on the EQ_5D questionnaire, therefore it 
provides an alternative measurement method of health outcomes by recycling EQ-5D 
data, which have been most frequently used for QALY measurement. Introducing the 
method can be efficient, while it does not preclude the evaluation of the acceptability 
of other aspects of health, such as capabilities necessary for broader wellbeing, or the 
dimensions missing from the current QALY concept. Last but not least, the benefit of 
the AH concept is that it relies on the opinion of the general population, therefore it is 
a suitable tool to provide transparent and relevant criteria required for legitimate 
decision making during the priority setting in healthcare financing.  
However, the precondition to the practical application of the AH concept is that its 
accurate and reliable measurement methods need to be developed. The separate 
evaluation of acceptable health states was a readily usable simple method during the 
initial exploratory studies of AH. However, health valuation methods evaluate the 
health states jointly. Therefore, for the reliable and valid measurement of AH we need 
to develop the method of joint evaluation.   
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Measuring AH is not based on traditional utility theories, its psychometric properties 
and its theoretical background for its application for health economic evaluations have 
yet to be developed.   
Proving the basic assumption, that in acceptable health gains are truly less valuable 
than in not acceptable health states is an important condition that we accept lower 
financing priorities for health gains in acceptable health states. Furthermore, for valid 
application of the method, we need to understand better the psychological processes 
during the evaluation task, and the factors influencing the evaluation of the 
acceptability of health states.  
The normative framework for the practical application of AH has not yet been firmly 
established yet. In harmony with known societal preferences, we can only accept the 
goal to get individuals to acceptable health. This is in accordance with the positive 
thesis of sufficientarian theory. According to utilitarianism, it is also important to get 
as many individuals to acceptable health as possible. AH is compatible with 
egalitarianism insofar as we consider equally important the treatment for all who are 
in not acceptable health states, while those, who are in acceptable health receive lower 
priority, regardless their age or the severity of their disease.  
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III. GOALS AND HYPOTHESES 
My thesis has two overarching goals in the development of the AH concept, and I 
have tested six hypotheses in connection with the primary research goals. 
1. Goal 1.: developing new measurement methods for AH, which are more accurate 
than previous techniques.  
1.1. Joint evaluation of the acceptability of discrete health states: instead of asking 
the acceptability of health states by dimension (separate evaluation), we 
evaluate the acceptability of joint health states displayed as vignettes 
containing different levels of the five EQ-5D dimensions, using an adaptive 
algorithm that selects questions based on the previous answers of respondents. 
In joint evaluation we aim to obtain a yes/no answers for all elements of the 
acceptability matrix (E-matrix). The E-matrix consists the acceptability 
information of 243 health states (constructed from the three levels on the five 
dimensions of the EQ-5D) across six ages from 30 to 80 years in 10-year 
intervals.  
1.1.1. Hypothesis 1 (H1): Using the adaptive algorithm, all elements of the 
E-matrix can be unequivocally determined for 90% of respondents. 
(Methods: page 55, results: page 62.) 
Hypothesis 2 (H2): With joint evaluation, people consider less problems 
acceptable compared to separate evaluation. (Methods: page 55, results: 
page 75.) 
1.2. Overall assessment of AH using the EQ VAS: the EQ VAS measures AH on 
a continuous scale on which 0 indicates the worst and 100 indicates the best 
imaginable health state.  
Hypothesis 3 (H3): When measured with the EQ VAS, people consider 
worst health states acceptable at older ages than at younger ages. 
(Methods: page 55, results: page 83.) 
2. Goal 2.: Exploring the association of AH and happiness. 
2.1. Measuring the association of the acceptability of individuals’ health states and 
their happiness.   
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Hypothesis 4 (H4): In acceptable states the level of health influences 
peoples’ happiness to a lesser extent than in not acceptable health states. 
(Methods: page 104, results: page 108.) 
2.2. Exploring the factors that affect the acceptability of individuals’ health states 
Hypothesis 5 (H5): Older individuals are more likely to consider their 
health acceptable than younger ones (Methods: page 104, results: page 
113.) 
Hypothesis 6 (H6): Individuals with worse subjective health consider 
their condition less acceptable than ones indicating better subjective 
health. (Methods: page 105, results: page 113.) 
 
 
 
 - 46 - 
IV. THE MEASUREMENT OF ACCEPTABLE HEALTH STATES 
IV.1. Background 
The first goal of my dissertation was to develop the methodology of the joint 
evaluation of acceptable health states. The EQ-5D-3L describes 243 discrete health-
states, out of which 232 (95.5%) contains problems in more than one dimension, as 
opposed to the health states included in separate evaluation. Since decision situations 
involving multiple attributes simultaneously or separately may result in different 
preferences (Hsee et al., 1999), our main assumption was that similarly to the 
valuation tasks of health-state utilities, by displaying EQ-5D profiles (Dolan, 1997),  
the joint evaluation of multiple helath problems will provide more reliable results than 
separate evaluation. The uncertainty of interpreting the results of separate evaluation 
is illustrated by the work of Wouters et al.  (Wouters et al., 2015) (Figure 4) In their 
research, the difference between AHCaggregate and AHCworst was nearly twice as big at 
age 70 as the 0.074 minimal clinically important difference (MCID) of the EQ-5D-3L 
UK-TTO value set, and it was nearly four times the MCID at age 80. Therefore, 
Wouters et al. measure the acceptability of three EQ-5D profiles, but they used a 
different evaluation logic, during the joint evaluation of profiles than during separate 
evaluation. Separate evaluation provided answers to the question: what percentage of 
people consider a health state acceptable in a given age. However, joint evaluation 
answered the question: what is the average age from which a discrete health state is 
acceptable (Wouters et al., 2015). The two approaches provided inconsistent 
acceptable health curves (Figure 4), therefore our goal was to develop a joint 
evaluation strategy, that is consistent with separate evaluation. As a solution, Wouters 
proposed the evaluation of the acceptability of several EQ-5D profiles. (Wouters et 
al., 2015) The 243 profiles in 6 ages provide 1458 health states, for which we apply 
the term E-matrix. We will refer to the elements of the E-matrix as health states, while 
the 243 different health states will be referred to as EQ-5D-3L profiles or simply 
profiles.  The first question was: how many and which health states should be 
evaluated in order to receive a satisfactory picture about the acceptability of the 1458 
health states?  
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Another part of the EQ-5D questionnaire is the EQ VAS health thermometer, which 
serves for the global evaluation of respondent’s current health status. While the EQ-
5D profiles enable the comparison between individuals, the EQ VAS provides 
numerical information about the individual’s current global health status (Feng et al., 
2014). In addition to the evaluation of the discrete health states of the E-matrix, we 
wondered, how the EQ VAS could be applied for the measurement of acceptable 
health.  
IV.2. Methods 
IV.2.1. Joint evaluation of discrete health states 
During planning our research, one potential approach was to ask the acceptability of 
the 1458 health states in a block-design. In an EQ-5D valuation experiment, university 
students evaluated all 243 profiles. The average time span was 86 minutes. In the DCE 
valuation of the EQ-5D 54 profiles are valued in pairs (27 questions), and the most 
profiles included in valuation studies were 47 (Yang et al., 2018). Since 1458 can be 
written as the product of 27 and 54, in case of 27 questions per respondent, for 
measuring acceptability with the 95%CI==±5% precision range we need to interview 
400*54=21600 individuals, while for 95%CI=±3% we need to involve 54000 
respondents. Therefore, we abandoned the block-design strategy.   
The next approach was the assembly of a standard set of questions. From a previous 
study in the general population, we had data from 9260 AHCaggregate curves obtained 
via separate evaluation (Péntek et al., 2009). Since the aggregate health state is the 
possible worst health state acceptable in a certain age, during joint evaluation we just 
need to focus on whether the aggregate health state is acceptable or not, and if not, 
then what combination of problems in less severe health states are acceptable. This 
can narrow down considerable the number of necessary questions. However, data has 
shown a rather heterogenous pattern: from the sample of 9260, we found 4600 
different AHCaggregate curves, and for evaluating all unknown health states, we would 
need to pose on average 94 questions per respondent. The number of possible 
questions per individual ranged between 0 and 1392. We concluded that with a 
standard questionnaire the accurate measurement of acceptable health problems is not 
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feasible. Before developing a prediction strategy from incomplete data, we aimed to 
gain as much information as possible.  
The final approach was the development of an adaptive questioning strategy, which 
would provide the most possible information about the acceptability of the 1458 health 
states using the fewest possible questions. Based on the results of EQ-5D studies in 
the normal population (Szende et al., 2014), we relied on the following assuptions 
when developing the adaptive questioning strategy:  
a) We can treat the dimensions of EQ-5D profiles as ordinal variables: in case of 
a consistent respondent, if a health state is acceptable in a certain age, then we 
can consider all health states acceptable, in which any level of any problems 
is the same or lower than the health state in question (better health states). 
Likewise: if a health state is not acceptable, then those health states are not 
acceptable either, in which the level of any problem is the same or higher than 
that of the health state in question (worse health states). We cannot deduct the 
acceptability of unknown health states in which both more and less severe 
problems coexist compared to the health state in question.  
b) Health deteriorates monotonously with age: in case of a consistent responder, 
if a health state is not acceptable in a certain age, then the same or worse health 
states are not acceptable either in that or younger ages. Vice versa: if a health 
states is acceptable in a certain age, then the same or better health state is 
acceptable in the same or older ages.  
The assumptions above enable us to gain information from the acceptability of more 
than one health states with a single question. The tested the efficiency of the model 
via computer simulation. From the AHCaggregate curves gained with separate evaluation 
from 9260 individuals, our model determined the unknown states according to the 
following rules:  
a) in every age, worse health states than aggregate health states were 
automatically considered not acceptable 
b) if problems were indicated as acceptable in a single dimension, then those 
problems and milder problems in the same dimension were considered 
acceptable, if no problems were acceptable in any other dimensions in the 
same age.  
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c) all other health states were considered unknown.  
Then, unknown health states were chosen randomly by the algorithm, and for each of 
them it assumed an acceptable / not acceptable answer for a hypothetical question with 
50-50% probability. The model posed 20 random questions and re-evaluated the 
acceptability of all health states after each question – narrowing down the pool of 
unknown health states before each consecutive question. The algorithm is depicted in 
Figure 6.  
Figure 6 Computer simulation model of the adaptive testing algorithm 
  
From the AHCaggregate data of the 9260 individuals we simulated the acceptability of 
13 501 080 health states (9260 individuals*243 profiles*6 ages). Without asking any 
questions, 92.3% of the health states were not acceptable, 1.2% were acceptable, and 
6.5% of them were unknown. After the simulation using 20 questions per respondent, 
the proportion of unknown states decreased to 0.06%, while for 96% of hypothetical 
respondents the acceptability of all health states could be determined (Figure 7). The 
differences between the AHCaggregate and AHCworst curves suggested that results are 
sensitive to the responses given to the 6.5% unknown health states, therefore we aimed 
to determine the acceptability of unknown health states as precisely, as possible.  
During the fieldwork, we considered the optimal number of health state evaluations 
during joint evaluation as many as subjects could still pay attention and maintain their 
collaboration. According to the results of the simulation, with 15 random questions in 
90% of subjects the acceptability of the 1458 health states could be fully determined, 
and the proportion of unknown states remained below 0.4%. Therefore, we decided 
to use a module of 15 questions during joint evaluation.  
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Figure 7 Results of the simulated adaptive testing 
 
Simulation based on AHCaggregate data of 9260 individuals. For each individual, the algorithm evaluated 
the acceptability of 1458 (altogether 13 501 080) health states. Left figure: with 15 simulated questions 
the acceptability of 99.6% of the 13 501 080 health states could be elicited. Right figure: with 15 
question the acceptability of all questions could be elicited for 90% of the simulated respondents.  
 
For displaying the results of joint evaluation, on the analogy of AHCaggregate and 
AHCworst, we constructed the Joint Acceptable Health Curve* (AHCjoint). After joint 
evaluation, we rendered the EQ-5D-3L index values (UK-TTO value set) to all 
acceptable health states, and in each age, we calculated from the lowest EQ-5D-3L 
index calculated for both individuals, and from their averages the sample AHCjoint.    
IV.2.2. Measuring AH with the EQ VAS instrument 
In case of electronic questionnaires, the display of visual analogue scales can 
influence the response pattern (Matejka et al., 2016), therefore we intended to modify 
the validated EQ VAS instrument as little as possible. On the EQ VAS thermomether 
respondents indicate their current health between the best (100) and worst (0) possible 
health states by drawing a straight line from a dot next to the middle of the 
thermometer. (Oppe and van Reenen, 2015) In VAS valuation studies respondents 
valued several health states on the same thermometer. Health states were placed on 
both sides of the VAS scale. (Brooks et al., 2003) In order not to influence responses 
placed on the vertical VAS thermometer, we arranged ages in a horizontal line in line 
with the middle of the scale (Figure 8). From acceptable VAS values we constructed 
the VAS acceptable health curve (AHCvas).  
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Figure 8 EQ VAS adapted to measuring AH 
 
Respondents had to link ages arranged horizontally at the middle of the scale with the levels of still 
acceptable health in respective ages. (0: worst imaginable health; 100 best imaginable health)   
IV.2.3. Questions of the „Health and Ageing” study 
In early 2018, we performed a cross-sectional survey via personal interviews among 
200 members of the Hungarian general population selected by convenience sampling. 
Subjects provided written consent, and data were collected anonymously. The 
research plan was approved by the Ethical Committee of the National Research 
Council (ETT-TUKEB) under the identifier: 5111-2-2018/EKU.  
We recorded acceptable health, respondents’ health status, their lifestyle and main 
socio-demographic variables.  
The questionnaire had two parts: we recorded via a computer-based questionnaire the 
separate and joint evaluation of acceptable health. Other variables, including the 
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acceptable VAS module, were recorded on a paper and pencil questionnaire. We 
coded all questionnaires and the database was created via joining the respondents’ 
answers anonymously. 
We collected the following information via an electronic questionnaire:  
a) Participant information and consent 
b) Separate evaluation of acceptable health problems 
c) Joint evaluation of acceptable health states 
d) Persons imagined during the evaluation of acceptable health (from multiple 
answers we formed three categories, whether respondents imagined only 
themselves, themselves and others or only others during the joint evaluation.  
 The joint evaluation module is depicted in Figure 9. Respondents had the opportunity 
to change their answers provided during separate evaluation.  
Figure 9 Joint evaluation module of AH 
 
Respondents evaluated the acceptability of health states presented in the black frame. The adaptive 
testing algorithm selected 15 questions randomly from the unknown states, based on the previous 
answers. Source: (Zrubka, 2018b). 
 
In the paper and pencil questionnaire we measured respondents’ subjective health with 
EQ VAS. Acceptable health was measured via the adapted EQ VAS between 30 and 
80-year-old age groups, in 10-year intervals. We divided respondents in 7 age groups: 
18-24, 25-43, 45-54, 55-74 and 75+. 
We also recorded the health status of respondents via the EQ-5D-3L questionnaire 
(EuroQoL Group, 1990) We analysed separately moderate and severe problems by 
each dimension, and also created an „any problem” category by counting moderate 
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and severe problems together. In a separate variable, we recorded if respondents 
indicated any problems in any of the dimensions. We also recorded the health state 
utilities (EQ-5D-3L index values) for each individual.  
For describing the socio-demographic status of respondents, we recorded the 
following data: age (and age group), gender, family status (married: married or lives 
in domestic partnership, vs. not married: single, divorced or widowed), education 
(tertiary: university of college degree, other: primary or secondary education), 
employment (employed: full or part-time, not employed: pensioner, student, 
housemaker), household income per capita. Based on data from the Central Statistical 
Office of Hungary, (KSH, 2015) we grouped respondents in the first two quintiles as 
having high income and ones in the remaining three quintiles as having low income.  
We described the lifestyle of respondents with behaviours associated with health risks: 
overweight (body mass index (BMI) >25) (Garrow, 1981)), smoking (at any quantity) 
(Schane et al., 2010)), excessive alcohol intake (men: >14 drinks / week or >4 drinks 
/ occasion, women >7 drinks / week, or >3 drinks/occasion (NIAAA)), lack of exercise 
((<150 minutes light exercise / week (WHO)).  
Furthermore, we asked questions potentially related to health attitudes: expected life 
span (own lifespan estimated by the respondent), life span of close relatives (<75 
years, >=75 years), informal caregiver status (ones who have provided care for free 
for at least 6 weeks for relatives or close friends), as well as the use of healthcare 
services during the 3 months preceding the interview.  
We also recorded happiness on a 0-10-point numeric scale, which is one of the 
simplest and most frequently used measure of subjective wellbeing. (Veenhoven, 
2009, Veenhoven, 2012) 
IV.3. Statistical methods used for the measurement of AH 
IV.3.1. Exploring the measurement properties of AH 
We analysed the sample and AH predominantly by descriptive methods, using 
abundant graphical illustration of the results. When displaying data, depending on the 
distribution we displayed mean and / or median, and for the description of dispersion, 
we showed the standard deviation or the interquartile range (IQR). The measurement 
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precision of AH measurements was described by the 95% confidence interval. 
Subgroups of the sample were compared with non-parametric tests, depending on the 
sample. We analysed the factors influencing the acceptability of problems via logistic 
regression, taking into consideration of the multilevel characteristics of the sample: 
for each respondent, we analysed the acceptability of the 1458 health states, clustering 
the standard errors on the level of the individual respondents, using robust standard 
errors. Model fit was checked via the Hosmer-Lemeshow test, its predictive properties 
were checked by the area under the ROC curve (AUC). The effect of response time 
on the acceptability of problems was analysed via a linear probability model, in which 
robust standard errors were clustered on the individual level. The explanatory 
variables were tested jointly by the Wald test in the model.  
IV.3.2. Hypothesis testing 
The first research goal was to develop new methods for the measurement of AH, 
which are more accurate compared to previous methods. We used the following 
methods for testing the corresponding hypotheses:  
H1: With adaptive testing we can determine the acceptability of all cells of the E-
matrix in 90% of subjects. During the preparatory simulation, we managed to 
determine the acceptability of all health states in 90% of the 9260 individuals, from 
whom AHCaggregate curves were available. We expected the same results from the 
interviews conducted with real respondents. We tested the hypothesis using the 95% 
exact binomial confidence interval. The expected value was p0=0,9, p1 is the 
proportion of respondents, for whom the acceptability can be determined for all cells 
of the E-matrix.  
We tested the following hypotheses:  
H0: p1=0,9 
Halt: p1≠0,9 
Our H1 hypothesis can be accepted in case H0 is accepted. (Results: page 62.) 
H2: When assessed via joint evaluation, people consider fewer problems acceptable 
compared to separate evaluation. Due to the non-normal distribution of the data, we 
tested the hypothesis by comparing median values of the AHCaggregate from separate 
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evaluation (Maggregate) and AHCjoint from joint evaluation (Mjoint) via the sign test, using 
p=0.05 significance level. Median values of the curves at all ages were tested jointly.    
H0: Maggregate=Mjoint 
Halt: Maggregate<Mjoint 
H2 can be accepted if H0 is rejected and Halt is accepted. (Results: page 75.) 
H3: When measured with the EQ VAS, people consider worse health states acceptable 
in older ages than in younger ages. Due to the high inter-individual variance of the 
level as well as slope of AHCvas, we tested the hypothesis using the following multi-
level regression model:   LMNOPQRS =  a+ bUVHWXYRS + gZR +  dUVHWXYRS ∗ ZR + µR +  tR ∗ UVHWXYRS +  eRS, 
where ageAHSik denotes age k, when respondent i evaluates acceptable health. We 
centred ageAHS at 30 years, therefore the intercept denoted with α represented the mean 
AHCvas at ageAHS 30. The individual variation of the level of AHCvas is denoted by μ, 
while β indicates the acceptable deterioration rate of health (ADR), and τ indicates the 
individual component of ADR. The vector Xi indicates the explanatory variables of 
individual respondent characteristics, the γ and δ coefficients denote the effect of 
individual explanatory variables on the level and slope of AHCvas, respectively. 
Individual variance of the level and slope are denoted by μ and τ respectively, which 
were modelled as random effects. We evaluated H3 based on the parameter value of 
β:   
H0: β=0 
Halt: β<0 
H3 can be accepted if H0 is rejected and Halt is accepted. (Results: page 83.) 
IV.4. Results 
IV.4.1. Demography and self-reported health of the sample 
The survey was completed by 200 respondents. Mean age was 43,3 years (±SD: 17,3 
years). The main socio-demographic characteristics of our respondents are 
summarized in Table 1. Compared to the Hungarian normal population, the sample 
was shifted towards individuals with higher education and high income. (KSH, 2011)  
The weight, and alcohol consumption of respondens was similar to the general 
population, while lack of exercise and smoking was somewhat less frequent compared 
 - 56 - 
to the expected value from the national health survey. (KSH, 2014) Respondents key 
lifestyle and health variables are summarized in Table 2.  
Table 1 Socio-demographic properties of the sample (n=200) 
Variable Category N % 
Age (n=200) 18-24 24 12.00 
 25-34 54 27.00 
 35-44 32 16.00 
 45-54 43 21.50 
 55-64 20 10.00 
 65-74 16 8.00 
 75+ 11 5.50 
Gender (n=189) Male 79 41.80 
 Female 110 58.20 
Education (n=199) Primary 9 4.52 
 Secondary 73 36.68 
 Tertiary 117 58.79 
Household income per capita 
(n=194) 
≤ 52 th HUF 5 2.51 
53-74 th HUF 12 6.03 
75-94 th HUF 27 13.57 
95-128 th HUF 35 17.59 
≥ 129 th HUF 120 60.30 
Percentages were calculated from the number of respondents with available data 
 
Based on the EQ-5D-3L dimensions, 44% of respondents indicated the presence of 
any health problems. Severe problems were reported by 4,5% of respondents. The 
frequency of problems in the respective EQ-5D dimensions were the following:  
a) Mobility – any problems: 17.5%, severe problems: 0.5% 
b) Self-care - any problems 1.5%, severe problems 0.5% 
c) Usual activities - any problems 9.5%, severe problems 1% 
d) Pain / discomfort – any problems 28.5%, severe problems 2.5% 
e) Anxiety / depression – any problems 33.5%, severe problems 1.5% 
The occurrence of health problems increased steeply with age, with the exception of 
anxiety / depression. Problems in the anxiety / depression dimension were abundant 
in the younger age groups, and their frequency did not increase as steeply as for other 
problems (Figure 10).  
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In every dimension respondents reported fewer problems compared to the national 
health survey recorded in 2000 (Szende and Nemeth, 2003). The comparison by age 
groups is shown in Table 3. Compared to the representative national health survey, 
anxiety / depression occurred more frequently in the youngest (18-24 years old) and 
mobility problems in the older (65+) age groups. There were fewer problems with 
self-care in our sample.  
Table 2 Lifestyle and health related characteristics of the sample 
Variable Category N % 
Lifestyle compared to others (n=200) Healthier 77 38.50 
 As healthy 103 51.50 
 Less healthy 20 10.00 
Body mass index (n=189) < 25 98 51.85 
 ³ 25 91 48.15 
Smoker (n=189) Yes 41 21.96 
 No 148 78.31 
High-risk alcohol intake (n=189) Yes 20 10.58 
 No 169 89.42 
Lack of exercise (n=189) Yes 105 55.56 
 No 84 44.44 
Lifespan of closest relatives (n=199) < 75 years 70 35.18 
 ³ 75 years 129 64.82 
Problems with health (n=199) Yes 89 55.28 
No 110 44.72 
Have used health services in past 3 months 
(n=199) 
Yes 117 58.79 
No 82 41.21 
Informal caregiver (n= 199) Yes 58 29.15 
 No 141 70.85 
Percentages were calculated from the number of respondents with available data 
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Figure 10 Occurrence of health problems in the EQ-5D-3L dimensions 
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Table 3 Prevalence of health problems compared to the representative national population 
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Mobility Any problems 0.0 0.9 3.7 4.6 6.3 8.6 14.0 21.2 35.0 30.3 50.0 39.6 90.9 57.6 
Severe problems 0.0 0.1 0.0 0.6 0.0 1.1 0.0 1.4 0.0 0.5 6.3 1.9 0.0 1.1 
Self-care Any problems 0.0 0.4 0.0 0.7 0.0 1.7 0.0 5.1 0.0 10.0 6.3 14.4 18.2 26.8 
Severe problems 0.0 0.0 0.0 0.3 0.0 0.2 0.0 1.0 0.0 1.3 6.3 2.8 0.0 3.8 
Usual activities Any problems 0.0 1.8 5.6 2.9 0.0 6.8 11.6 16.7 10.0 22.3 25.0 28.8 45.5 44.2 
Severe problems 0.0 0.4 0.0 0.4 0.0 1.2 0.0 2.1 0.0 3.7 6.3 6.0 9.1 8.7 
Pain / 
discomfort 
Any problems 4.2 14.5 16.7 18.5 12.5 30.5 25.6 46.1 60.0 54.8 68.8 61.1 81.8 69.6 
Severe problems 0.0 0.1 0.0 0.7 0.0 1.2 4.7 3.3 5.0 4.6 0.0 8.6 18.2 10.1 
Anxiety / 
depression 
Any problems 37.5 17.0 22.2 23.9 31.3 29.9 27.9 39.5 55.0 47.1 43.8 47.0 54.5 54.9 
Severe problems 4.2 1.2 1.9 2.3 0.0 1.8 0.0 4.0 5.0 5.5 0.0 6.5 0.0 7.5 
Population: National Health Survey, 2000 (OLEF) (Szende and Nemeth, 2003) 
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Compared with the national health survey from year 2000 (Figure 11), the EQ VAS 
values in our sample were higher with the exception of the 18-24-year-old group. The 
EQ-5D index values using the European VAS value set were similar to those in the 
national health survey (Szende and Nemeth, 2003).  
Figure 11 Health status of our sample vs the Hungarian general population 
 
Population: National Health Survey, 2000 (OLEF) (Szende and Nemeth, 2003) 
 
The mean level of happiness was 7,3 (±SD: 2,0), with level 8 reported most frequently.  
Happiness scores were slightly left-skewed and showed a mild declining trend with 
age (Figure 12). 
 
IV.4.2. Efficiency of adaptive testing (H1) 
We evaluated the acceptability of 1458 discrete health states for each of the 200 
respondents. Altogether we collected 291600 data points. After separate evaluation, 
91,7% of health states were not acceptable (on average 1336.2 per respondent), 1,3% 
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unknown. Compared to simulation run on the AHCaggregate data from a national sample 
of 9260 respondents (n=93), in our sample the mean number of unknown states was 
greater (n=103). During joint evaluation, the algorithm asked on average 11,09 
questions from each respondent. For 43,5% of respondents, (n=87) 15 or fewer 
questions were sufficient to evaluate the acceptability of all health states of their E-
matrix in question.  
The first hypothesis (H1) of the research was that the acceptability of all health states 
could be fully determined for 90% of individuals. In case of 200 respondents, the 95% 
exact binomial confidence interval for the 90% acceptability rate falls between 85,0-
93,8%. Our results fell below the lower 95% CI limit, outside the expected range. 
Therefore, we did not accept our H1 hypothesis: the efficiency of adaptive testing was 
inferior compared to our expectations.  
During joint evaluation we could elicit the acceptability of 67.4% of the unknown 
states, on average 69.4 states per respondent. During joint evaluation we could 
determine the acceptability of 6.25 health states by each question.  
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Figure 12 Happiness of our respondents 
 
Happiness of respondents was measured on the 0-10 numeral scale. Left figure: distribution of 
happiness scores. Right figure: bold line – mean happiness with age; dashed line – linear trend of 
happiness with age 
Respondents evaluated 70.2% of the randomly displayed health states during joint 
evaluation as acceptable, while 29.8% as not acceptable. After joint evaluation, as 
opposed to the 0.4% estimated value from the simulation assuming 50% probability 
of acceptance, 2.3% of the health states remained unknown, so the adaptive algorithm 
in practice performed below the expectation. On average, 33.6 health states per 
respondent (32.6% of unknown health states after separate evaluation) remained 
unknown after joint evaluation.  
Respondents spent on average 110 seconds answering the questions of separate 
evaluation (median: 96 sec). The number of questions in separate evaluation was 10 
for all respondents (in five dimensions the acceptability of moderate and severe 
problems), therefore it took on average 11 seconds to provide answer for each question 
(median: 10 sec).  Joint evaluation took on average 175 seconds, (median: 166 sec), 
mean response time per question was 18 sec (median: 14 sec). The evaluation of 
discrete health states (separate and joint evaluation with explanations) took on average 
392 seconds from respondents (median: 349 sec), the mean time spent answering the 
survey was 19 seconds per question (median: 16 sec). Figure 13 displays the 
distribution of response times.  
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During separate evaluation, questions remained mainly about the acceptability of 
moderate health problems. The proportion of health states elicited during separate and 
joint evaluation, and the distribution of unknown health states within elements of the 
E-matrix are displayed in Figure 14. In case of 71.9% of the elements of the E-matrix, 
the percentage of unknown states was below 1%. For 9.7% of the E-matrix elements, 
the percentage of unknown states was over 10%. The maximum percentage of 
unknown states was 20.0%.  
Figure 13 Distribution of the number of questions and response times of health 
state evaluation 
 
Top left figure: distribution of the number of questions during joint evaluation. In 43.5% of 
respondents, less than 15 questions were enough for eliciting the acceptability of all health states. Top 
right and bottom figures: distribution of time spent with separate evaluation, joint evaluation and the 
total time of the two tasks by the % of respondents 
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The unknown states remaining after joint evaluation showed association with the 
severity of the profile and age. The acceptability of eleven EQ-5D-3L profiles was 
determined unambiguously during separate evaluation (those profiles, in which health 
problems occurred only in a single dimension and full health). For the remaining i 
health states of combined problems, we evaluated the association between the 
proportion of unknown health states (ui) with the severity of problem (s: EQ-5D-3L 
index, UK-TTO value set), age (k=age-30years), their quadratic terms and interactions 
with the following linear probability model:  
ui=a + b1si2 + b2ki + b3ki2 +b4si*ki+b5si2*k+b6si*ki2 +b7si2*ki2 + e 
The whole model (F(8,653)=179.5, p<0.001), all main effects and interactions were 
significant (Wald test), the explanatory power of the model was high (R2=0,6874). 
The heatmap from the proportion of unknown states is illustrated in Figure 15. Among 
moderate health sates mainly in ages of 60-70 years, and among more severe problems 
in the 80-year-old age group remained relatively high the proportion of unknown 
health states. This association can be used to design more efficient adaptive testing 
algorithms in the future.  
Figure 14 Distribution of unknown health states 
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Left figure: on the horizontal axis we ordered the 243 EQ-5D-3L profiles according to their UK-TTO 
index values, and on the vertical axis we indicated the proportion of health profiles (n=1200, 200 
respondents * 6 ages), for which the acceptability could be elicited during separate evaluation (white), 
joint evaluation (grey) or which remained unknown after joint evaluation (dark grey). Right figure: the 
horizontal axis shows bands of percentages of health states that remained unknown after joint 
evaluation (elements of the E-matrix, n=1458, 243 EQ-5D profiles* 6 ages). The vertical axis shows 
the corresponding percentages of the 1458 health states falling in each band.    
 
In order to understand, how the proportion of unknown health states influences the 
precision of measuring AH (proportion of acceptable health states), we determined 
the 95% confidence interval (95%CIi) for all i elements of the E-matrix according to 
the following:  
 
95%$%& = 1,96 ∗ ,-& ∗ (1 − -&)1 ∗ (1 − 2&)  
 
where pi denotes the proportion of acceptable health states, and ui denotes the 
proportion of unknown health states diminishing the effective sample-size within each 
health state.  
We modelled the effects of decreasing the amount of unknown health states by 50, 90 
and 100%, as well as increasing the sample size from 200 to 400, 1000 and 2000. For 
a sample size of 200, we could determine the acceptability of health states with at least 
±7% 95%CI precision. Decreasing the proportion of unknown states improved this 
only to a small extent. However, increasing the sample size brought dramatic 
improvement of precision (Figure 16).  
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Figure 15 Distribution of unknown health states 
 
The heat map illustrates the elements of the E-matrix: the horizontal axis shows six ages, the vertical 
axis shows 243 EQ-5D-3L health profiles, in increasing order of UK-TTO index values. Colours 
indicate the proportion of unknown health states. Dark colours indicate greater proportion of unknown 
health states. The highest percentage of unknown states was 20% (black), in case of white fields the 
acceptability for all health states could be elicited.  
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Figure 16 Exploring the precision of AH measurement 
 
 
We characterised the measurement precision of AH with the 95%CI of the proportion of acceptable 
health states within each element of the E-matrix (1458 health states, 243 EQ-5D-3L profiles*6 ages). 
Grey bars show the distribution of the measurement precision of the 1458 health states from our sample 
of 200 respondents. The white bars depict the changes of the measurement precision by changing the 
number of unknown health states – which can be achieved by improving the efficiency of the adaptive 
testing algorithm (left column) or increasing the sample size (right column).  
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IV.4.3. Measuring the acceptability of health problems via separate evaluation 
According to the separate evaluation, the acceptability of moderate and severe health 
problems increased with age. The acceptability of moderate problems showed 
dramatic increase after 60 years, and that of the severe problems increased 
dramatically from 80 years of age. Severe problems were less acceptable than 
moderate ones. In ages 30, 60 and 80 years, according to 10.5%, 62.5% and 99.5% of 
respondents was at least one health problem acceptable, respectively. At least one 
severe problem was acceptable at 30, 60 and 80 years according to 2.5%, 12.5% and 
65.5% of respondents. Details are shown in Figure 17.  
Figure 17 Acceptability of health problems by separate evaluation 
 
Left figure: the percentage of respondents with at least one problem in any of the five EQ-5D-3L 
dimensions, Right figure: the percentage of respondents with at least one severe problem in any of the 
five EQ-5D-3L dimensions, 
 
Table 4 summarizes the acceptability of problems in each EQ-5D-3L dimension. Most 
frequently moderate problems with mobility were accepted, while severe problems 
were accepted most frequently in the dimension of usual activities. In younger ages 
anxiety/depression was the most frequently acceptable problem, but in this group was 
the highest the proportion of those, who do not accept even moderate problems.   
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Table 4 Acceptability of health problems in different ages: separate evaluation 
  Age (year) 
 
 
30 40 50 60 70 80 Never 
Mobility Any 0.5 1.5 16 38 75.5 96 4 
Severe 0 0 0.5 0.5 8 31.5 68.5 
Self-care Any 0.5 0.5 1.5 6.5 32.5 83.5 16.5 
Severe 0 0 0.5 0.5 3 32 68 
Usual activities Any 0 1 3 21 63.5 95.5 4.5 
Severe 0 0 0 0.5 4 49 51 
Pain / 
discomfort 
Any 2 6.5 18.5 41.5 71.5 88.5 11.5 
Severe 0.5 0.5 2 5.5 20 45.5 54.5 
Anxiety / 
depression 
Any 9.5 16 23.5 43 61.5 78.5 21.5 
Severe 2.5 4.5 6.5 9.5 17.5 40.5 59.5 
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Figure 18 Acceptability of health problems in separate evaluation 
  
HU: our sample, NL: Dutch population, RA: Hungarian patients with rheumatoid arthritis.   
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We compared our results of separate evaluation with data measured with the same 
method in the Dutch general population (Wouters et al., 2015) and among Hungarian 
patients with rheumatoid arthritis (Pentek et al., 2014b). The acceptability of severe 
problems was remarkably similar in the three populations. Chronic patients accepted 
somewhat more problems in the dimensions of self-care, usual activities and pain / 
discomfort. The Dutch population accepted less anxiety / depression than Hungarians. 
(Figure 18).  
IV.4.4. Acceptability of health states by joint evaluation 
The results of joint evaluation were presented in the following international 
conference poster: (Zrubka et al., 2018b) 
The number of health states elicited during joint evaluation are shown in Figure 19. 
After separate evaluation in each age on average 3.1 health states were acceptable 
automatically, 17.2 health states were unknown and 222.7 were not acceptable. The 
share of unknown health states increased with age, in 80 year olds the mean number 
of automatically acceptable health states was 7.4 and the mean number of unknown 
states was 78.5. During joint evaluation from the mean 17.2 unknown states by age 
our respondents considered 3.5 as not acceptable (20.1%), 8.1 as acceptable (47.3%) 
and the acceptability of 5.6 health states remained unknown (32.6%). The odds ratio 
between acceptable / not acceptable answers during joint evaluation was 2.35 (95%CI: 
2.27-2.44). Figure 19 illustrates the health states which are used for the calculation of 
the AHCaggregate, AHCworst and AHCjoint health curves. AHCworst takes the lowest EQ-
5D-3L index value of the automatically acceptable health states, AHCaggregate takes the 
lowest EQ-5D-3L index value from the unknown states after separate evaluation, and 
AHCjoint takes the lowest EQ-5D-3L index value of acceptable health states after joint 
evaluation.  
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Figure 19 Results of joint evaluation 
 
  
Columns show the number of elicited and unknown health states by age after joint evaluation. From 
the 243 EQ-5D-3L profiles in 80 years of age after separate evaluation on average 7.4 health states 
were acceptable (dark grey) and 78.5 health states were unknown. After joint evaluation, from this 38.9 
health states became acceptable (medium grey), 17.4 health states became not acceptable (light grey) 
and 22.2 health states remained unknown. The markers show the health states used for the calculation 
of the acceptable health curves. AHCworst (circle)  is the mean of the lowest EQ-5D-3L index values 
of the automatically acceptable health states for each respondent, AHCaggregate (triangle) is the mean 
of the lowest EQ-5D-3L index values from the unknown states after separate evaluation, and AHCjoint 
(diamond) is the mean of the lowest EQ-5D-3L index values of acceptable health states after joint 
evaluation. 
 
According to our expectations, AHCjoint fell among the AHCaggregate and AHCworst 
curves (Figure 20). All three curves confirmed that people accept more health 
problems as age advances. The differences between the three curves suggest that the 
adequate method for measuring AH is the joint evaluation of health states, since the 
aggregation of health problems after separate evaluation (AHCaggregate) overestimates 
the amount of acceptable health states, while people are willing to accept some 
combinations of health problems, therefore AHCworst underestimates the amount of 
acceptable health problems.  
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Figure 20 AHCjoint health curve (H2) 
 
AHCworst is the mean of the lowest EQ-5D-3L index values of the automatically acceptable health 
states for each respondent, AHCaggregate is the mean of the lowest EQ-5D-3L index values from the 
unknown states after separate evaluation, and AHCjoint is the mean of the lowest EQ-5D-3L index 
values of acceptable health states after joint evaluation. 
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Figure 21 Distribution of the values of acceptable health curves (AHC) 
 
The three acceptable health curves (AHCjoint, AHCworst, AHCaggregate) were calculated from the mean of 
individual AHCjoint, AHCworst and AHCaggregate health states. The histograms show the distribution of 
individual AHC states for the 200 respondents.  
 
Figure 21. shows that the distribution of individual values of all three AHCs are 
strongly left-skewed, therefore we compared the curves with non-parametric methods.  
The second hypothesis (H2) was that by joint evaluation people considered fewer 
health problems acceptable when compared to separate evaluation, meaning that 
median values of AHCaggregate are lower than those of the AHCjoint. The results of 
the sign test of the differences of medians (Maggregate, Mjoint) were summarized in 
Table 5.   
Table 5 Sign test comparing median values of AHCaggregate and AHCjoint  
 
Mjoint-Maggregate Outcome (N) Expected (N) 
 >0 148 74 
 <0 0 74 
 =0 52 0 
Total 200 200 
 
If Mjoint > Maggregate, the exact binomial probability of the result (Mjoint- Maggregate >0, 
N=148) is p<0,001, therefore we rejected the null-hypothesis (H0: Maggregate=Mjoint) 
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and accepted the alternative hypothesis (Halt: Maggregate<Mjoint). So, we could accept 
H2: with joint evaluation people consider fewer health problems acceptable than with 
separate evaluation.  
The sign test comparing median AHCaggregate and AHCjoint values was significant 
already from age 40 (p=0.002). When comparing with the sign test, the median 
AHCjoint values in all ages jointly were significantly lower than those of AHCworst 
(p<0.001), and the comparison by ages was significant from age 40 (p=0.0039).  
IV.4.5. Accuracy of the joint evaluation of AH 
Between the three acceptable health curves created after separate and joint evaluation 
(AHCaggragate, AHCworst and AHCjoint) the difference was significant from 40 years of 
age. The accuracy of AHCjoint measurement of determined by the following three 
factors:  
a) Residual inaccuracy from the unknown health states remaining after joint 
evaluation, which may influence the levels of respondents’ individual AHCjoint 
values.  
b) The dispersion of Az AHCjoint values, which is determined by the size and 
composition of the sample 
c) The uncertainty arising from the measurement problems of the utility values 
rendered to acceptable health states.  
From the above three, during the measurement of AH we can influence only the first 
two. The measurement properties of EQ-5D-3L utility values falls under the realm of 
EQ-5D valuation studies (Brooks et al., 2003). 
We estimated the magnitude of inaccuracy arising from residual unknown health after 
joint evaluation by the following steps:  
a) We can render to all elements of the E-matrix a single AHCjoint value (profile 
with the lowest EQ-5D-3L value in each age).  
b) We calculated the EQ-5D-3L index values for all unknown elements of the E-
matrix. 
c) We took the difference of AHCjoint values and the EQ-5D-3L index values of 
the unknown health states. The distribution of the differences is depicted on 
the left side of Figure 21. The difference was positive, if the EQ-5D-3L index 
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values were higher than AHCjoint. Eliciting these health states does not change 
the AHCjoint curve, because it is calculated from the lowest EQ-5D-3L index 
values of the elicited health states.  
d) The difference was negative, if the EQ-5D-3L index value of known health 
states was lower than AHCjoint. These health states could modify AHCjoint, if 
the respondent evaluated them as acceptable.  
e) So, we could get the theoretical minimum of AHCjoint, if all residual unknown 
health states were evaluated as by the respondent as acceptable. Possible 
values of AHCjoint fall anywhere between the theoretical minimum and the 
known AHCjoint curve.  
The right graph of Figure 22 illustrates the theoretical minimum and possible range of 
AHCjoint values in addition to the known AHCjoint and AHCaggregate. The question was 
whether by eliciting all unknown health states, the difference between AHCjoint and 
AHCaggregate would remain significant, which could prove without actually eliciting 
the unknown health states, that a module of joint evaluation with 15 questions results 
a different AHCjoint from the results of separate evaluation. In the opposite case, one 
could argue, that the difference between the AHCs can be explained by the fact that 
certain health states remained unknown during the joint evaluation exercise.  
We compared the three curves with the sign test, similarly to the method used when 
testing H2. The difference between the median values of AHCaggregate and the 
theoretical minimum of AHCjoint was significant for all ages jointly, and from 50 years 
in each age group (p≤0.001). The difference between the known AHCjoint and the 
theoretical minimum of AHCjoint was also significant both for all ages jointly, and from 
40 years in all ages (p≤0.032).  This result supports the assumption that joint 
evaluation leads to different result compared to separate evaluation, even without 
eliciting all unknown health states. During the joint evaluation of AH, compared to 
the aggregation of problems regarded as acceptable in separate evaluation, people 
accept fewer problems. However, the EQ-5D-3L index difference between the known 
AHCjoint values and the theoretical minimum of AHCjoint was 0.09, which is greater 
than the minimally important clinical difference (MCID) of 0.074 for EQ-5D-3L 
(Pickard et al., 2007). This result draws attention to the importance of the goal to 
further decrease the remaining number of unknown health states after joint evaluation, 
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in order to avoide statistically and clinically significant difference between the 
theoretical minimum and the actually measured AHCjoint curves.  
Figure 22 Accuracy of the measurement of AHCjoint  
 
Left figure: the distribution of the differences of AHCjoint values and unknown health states in each age 
for the 200 respondents. If the unknown health states falling on the left side of the dashed line would 
be acceptable, then the AHCjoint curve would change. The EQ-5D-3L index values of unknown states 
on the right of the dashed line are higher than those of the AHCjoint, therefore their acceptability does 
not influence the AHCjoint curve. Right figure: the bold line indicates the AHCjoint, the dashed line the 
AHCaggregate, and the grey area the possible values of the AHCjoint depending on what proportion of the 
unknown health states would be evaluated as acceptable by the respondents. The lowest EQ-5D-3L 
index values of the grey area show the AHCjoint in the case if all unknown health states were considered 
acceptable by the respondents.  
 
The accuracy of AH measurement explained by sampling can be described by the 
dispersion of AHCjoint and AHCaggregate values (Figure 23, left diagram). Given the 
strong left-skew of the distributions, we displayed median values of the curves, and 
we depicted the interquartile range (IQR) as a measure of dispersion. From the curve 
we can read that the dispersion of AHCjoint is smaller at older age groups than the 
dispersion values of AHCaggregate.  The IQR of AHCjoint at the 70 and 80-year-old age 
groups was 0.38 and 0.62, while that of AHCaggregate was 0.63 and 0.87, 
respectively.  
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We can treat AHCaggregate as a hypothetical maximum of AHCjoint in the case when the 
number of questions in joint evaluation is 0 instead of 15.  So, the difference between 
the dispersion of AHCaggregate and AHCjoint is given by the individual variance of the 
differences between the latent AH threshold and the artificially constructed 
AHCaggregate curve given from the responses to separate evaluation questions.  Some 
respondents accepted the problems in combination as well which they considered 
acceptable during separate evaluation. However, there were respondents, who, having 
seen the health state vignettes during joint evaluation, asked for the modification of 
their responses to questions of the separate evaluation module. By decreasing the 
number of unknown health states, the variance of AHCaggregate due to different 
response strategies during separate evaluation can be decreased. Furthermore, 
understanding the factors that influence the individual response strategies, or even 
estimating them during the evaluation process could support the development of a 
more efficient adaptive testing algorithm.  
 
IV.4.6. Comparison of AH and respondents self-rated health 
We compared AHCjoint with respondents self-rated health by the EQ-5D-3L (UK-TTO 
value set) (Figure 23, right graph) The two curves overlapped until the age of 60. In 
the 70 and 80-year-old age groups, our respondent rated their health better than the 
acceptable health curve. The IQR values of AHCjoint were smaller until age 50, and 
larger beyond age 70 than the IQR of self-rated health. These results suggest, that the 
imagination of respondents about acceptable health in younger ages is relatively 
homogenous, while the imaginations about acceptable health states in older ages show 
greater variability than that of the health states actually experienced by our 
respondents.  
We also compared the AHCjoint with the results of the National Health Survey 
Szende and Nemeth, 2003). Up to age 50 our respondents considered on average 
better, while above 70 years of age worse health states acceptable, than the health 
status of the general population. During the comparison, we calculated the AHCjoint 
curve with the European VAS value set, which was used in the National Health Survey 
(Figure 26., left graph) 
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Figure 23 Comparison of AHCjoint with health variables of the sample 
 
Left figure: comparison of AHCjoint (black bold line) and AHCaggregate (grey dashed line). The curves 
represent the means, diamonds represent the medians and error bars represent the IQR. Right figure: 
comparison of AHCjoint (black bold line) and respondents’ corresponding EQ-5D-3L values (grey 
dashed line). We depicted the 24-34 years age group of respondents next to the AHCjoint measured at 
30 years. The curves represent the means, diamonds represent the medians and error bars represent 
the IQR.  
IV.4.7. Measuring AH with the adapted EQ VAS instrument  
The two chapters below are based on our published results about using the EQ VAS 
for the measurement of AH (Zrubka et al., 2018c, Zrubka et al., 2019d). 
We had acceptable VAS data from 196 respondents. The acceptable VAS (AHCvas) 
values at age 30, 40, 50, 60, 70 and 80 were 92.5, 87.3, 80.3, 73.4, 65.2 and 56.7, 
respectively (Figure 24).  
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Figure 24 Acceptable VAS health curve (AHCvas) 
 
The AHCvas values reinforced the results measured with the discrete health states: 
people consider more problems acceptable with age. The AHCjoint and AHCvas curves 
within the limits of their measurement range showed similar spread, their dispersion 
values were similar, however, their shape was different. While AHCjoint obtained via 
the evaluation of discrete health states indicated minimal amount of acceptable 
problems up to the age of 50 years, which was followed by a steep decline of AH, the 
AHCvas showed a quasi-linear course, which suggests that people on average consider 
an even rate of health deterioration acceptable in each decade (Figure 25, left graph)  
Our respondents above 40 years of age considered their own health measured by the 
EQ VAS similar to the level of acceptable health. The dispersion of the curves was 
also similar. In the 30-year-old age group, however, the sample’s own health was 
worse compared to the level considered acceptable for their age (Figure 25, right 
graph).  
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Similarly to the self-reported health of our sample on the EQ VAS, the level of 
acceptable health was higher compared to the EQ VAS measured in the general 
population (Szende and Nemeth, 2003) (Figure 26, right graph).  
Figure 25 Comparison of AHCvas with health variables of the sample 
 
Left figure: comparison of AHCjoint (black bold line) and AHCvas (grey dashed line). The left vertical 
axis shows the possible extreme values of AHCjoint (EQ-5D-3L index, max:1, min: -0.594), the right 
vertical axis shows the extreme values of AHCvas (max:100, min:0). The curves represent the means, 
diamonds represent the medians and error bars represent the IQR. Right figure: AHCvas is depicted 
next to responders’ own EQ VAS scores. The AHCvas measured at 30 years corresponds to the EQ 
VAS values of the 25-34-year-old age group.  
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Figure 26 Comparison of AH and population norms 
 
Population norm: National Health Survey (Szende and Nemeth, 2003) The AHCvas measured at 30 
years corresponds to the EQ VAS values of the 25-34-year-old age group.  
 
IV.4.8. Factors influencing AHCvas (H3) 
 
We analysed the AHCvas via multilevel regression. Results are summarized in Table 
6. We estimated the model (detailed in IV.2.6.c) in steps. In the baseline model (M1) 
the intercepts and slopes of individual AHCvas curves differed significantly. The 
AHCvas at year 30 was 93.4 points (±SD=8.7) (p<0,001). AHCvas showed on average 
7,2 points decline in every 10 years.  (bageAH=-0,723, p<0,001). Since in all further 
models including explanatory variables the bageAH was significant and negative, we 
accepted H3: people consider worse health states acceptable in older ages compared 
to younger ages.  
We examined the effects of respondents’ individual characteristics in four groups. 
Individual factors explained only a small amount of the model variance: in the full 
model containing all explanatory variables (M5), 2/3 of the variance of the intercept 
and ¾ of the variance of the slope was not explained. Holding all other parameters 
fixed, the explanation of the M5 coefficients is the following:  
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a) Base model characteristics: 35-64-year-old man, secondary education, EQ 
VAS=80.5, not high-risk drinker, non-smoker, body mass index below 25, 
does exercise regularly, imagined himself during the evaluation of AH, his 
relatives died before the age of 75 and he is not an informal caregiver.  
b) Younger individuals indicated worse health states acceptable at 30 years 
compared to the 35-64-year-old reference group, while they considered 
slower deterioration of health acceptable.  
c) The self-reported health of respondents influenced significantly both the level 
of AHCvas and the slope of the curve. Individuals, who rated their health 
better than average on the EQ VAS, considered higher level of health and 
slower deterioration acceptable compared to the base model, than those had 
worse health than average.  
d)  The lifestyle of respondents influenced acceptable health only to a small 
extent: ones who do not exercise regularly and who are overweight (body 
mass index >25) considered a steeper acceptable deterioration rate of health. 
High risk drinkers considered less steep deterioration of health acceptable.  
e) The reference person respondents imagined during the evaluation of 
acceptable health also influenced the level of acceptable health. Ones who 
imagined themselves, considered higher level and slower deterioration of 
health acceptable compared to those, who imagined others.  
f) Individuals’ experiences with their surroundings also influenced their opinion 
about AH: the lifespan of close relatives, and informal caregiver status (close 
relationship with ill or old individuals) also significantly influenced the 
amount of acceptable health.  
  
 - 84 - 
Table 6 Multilevel regression of AHCvas 
 
 
M1 M2 M3 M4 M5 
1st level 
parameters Intercept 93.87*** 95.76*** 92.71*** 94.39*** 96.71*** 
  (0.662) (1.481) (1.770) (1.856) (2.037) 
 ageAH -0.723*** -0.757*** -0.751*** -0.696*** -0.734*** 
  (0.0258) (0.0587) (0.0713) (0.0754) (0.0822) 
2nd level 
parameters: 
intercept Respondents’ age: 18-34  -4.143*** -4.654*** -4.564*** -4.636*** 
   (1.398) (1.315) (1.312) (1.318) 
 Respondents’ age: 65+  -0.148 3.372* 2.472 2.673 
   (2.023) (1.968) (1.969) (2.000) 
 Female gender  0.687 0.864 0.660 0.686 
   (1.317) (1.278) (1.269) (1.257) 
 Tertiary education  -1.053 -1.238 -1.026 -0.856 
   (1.321) (1.212) (1.204) (1.193) 
 Self-rated health (EQ VAS) i   0.280*** 0.268*** 0.271*** 
    (0.0468) (0.0463) (0.0456) 
 High risk alcohol   1.032 0.406 0.0466 
    (2.056) (2.038) (2.012) 
 Smoking   2.114 2.320 2.553* 
    (1.557) (1.538) (1.527) 
 Lack of exercise   1.024 0.796 0.305 
    (1.244) (1.238) (1.243) 
 Body mass index > 25   3.220** 3.455*** 3.501*** 
    (1.312) (1.295) (1.289) 
 Persons imagined: own and others     -2.844* -2.825* 
     (1.577) (1.585) 
 Persons imagined: others    -3.101** -2.640* 
     (1.377) (1.368) 
 Close relative’s life span >75y     -3.061** 
      (1.272) 
 Informal caregiver     -1.123 
      (1.415) 
2nd level 
parameters:  
slope Respondents’ age: 18-34  0.0832 0.0663 0.0754 0.104* 
   (0.0556) (0.0531) (0.0534) (0.0534) 
 Respondents’ age: 65+  -0.0554 0.0582 0.0360 -0.0180 
   (0.0802) (0.0793) (0.0799) (0.0808) 
 Female gender  -0.0111 0.00923 0.0116 0.00213 
   (0.0523) (0.0516) (0.0516) (0.0509) 
 Tertiary education  0.0228 0.00741 0.0123 0.0119 
   (0.0524) (0.0489) (0.0489) (0.0483) 
 Self-rated health (EQ VAS) i   0.00743*** 0.00696*** 0.00690*** 
    (0.00189) (0.00188) (0.00185) 
 High risk alcohol   0.150* 0.132 0.143* 
    (0.0828) (0.0827) (0.0813) 
 Smoking   -0.0219 -0.0229 -0.0421 
    (0.0629) (0.0627) (0.0620) 
 Lack of exercise   -0.125** -0.132*** -0.140*** 
    (0.0503) (0.0503) (0.0503) 
 Body mass index > 25   0.0894* 0.0899* 0.0699 
    (0.0529) (0.0527) (0.0522) 
 Persons imagined: own and others     -0.0558 -0.0343 
     (0.0644) (0.0645) 
 Persons imagined: others    -0.138** -0.142** 
     (0.0559) (0.0552) 
 Close relative’s life span  >75y     0.00713 
      (0.0517) 
 Informal caregiver     0.166*** 
      (0.0572) 
Random 
effects 
parameters Variance (ageAH) 0.1174*** 0.1157***   0.0971***   0.0951*** 0.0912*** 
  (0.0131) (0.0130) (0.0110) (0.0109) (0.0105) 
 Variance (Intercept)  75.483*** 70.870***  56.961***  54.746***  52.875***  
  (8.697) (8.257) (6.813) (6.633) (6.446) 
 Covariance (Intercept. ageAH)  0.0414  0.1486  -0.2336  -0.3204*  -0.2828  
  (0.2383) (0.2302) (0.1965) (0.1943) (0.1880) 
 AIC 7657.354 7624.635 7522.899 7401.364 7352.859 
 Observations (N) 1.145 1.139 1.133 1.115 1.109 
 Number of respondents 194 193 192 189 188 
Standard errors in parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
i: Self-rated health was measured on EQVAS and was centred to the sample mean 
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IV.4.9. Az E-matrix 
During the joint evaluation we elicited the acceptability of all health states. The E-
matrix is shown in Table 7. The most frequently acceptable health state was 21111 
(moderate problems with mobility), which was acceptable by 96% of respondents in 
80 years of age. The worst health state described by EQ-5D-3L (33333: severe 
problems in all dimensions) was also acceptable by 0.5% of respondents in 80 years 
of age (a single respondent from the sample of 200). Figure 27 depicts the 
acceptability of problems by age and problem severity, measured by the EQ-5D-3L 
index. Health states with lower EQ-5D-3L index values than 0.5 were acceptable 
nearly exclusively from 80 years of age. Below 50 years, the acceptability of the health 
state with highest utility (11211, moderate problem with usual activities) was below 
10%. Certain respondents considered worse than dead health states acceptable above 
80 years of age. We rounded the EQ-5D-3L index values of problems to 0.05 precision 
on the graph.  
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Figure 27 Severity and acceptability of health problems in different ages 
 
We rounded the EQ-5D-3L index values of all 242 EQ-5D-3L profiles to 0.05 precision and ranked in 
increasing order on the horizontal axis. The vertical axis shows the probability of being acceptable in 
10-year age bands.   
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Table 7 E-matrix 
 Age   Age   Age 
 Profile 30 40 50 60 70 80    Profile 30 40 50 60 70 80    Profile 30 40 50 60 70 80 
11111 100 100 100 100 100 100   21111 0.5 1.5 16 38 75.5 96   31111 0 0 0.5 0.5 8 31.5 
11112 9.5 16 23.5 43 61.5 78.5   21112 0 0 2.5 12.5 41 70.5   31112 0 0 0 0 2.5 19 
11113 2.5 4.5 6.5 9.5 17.5 40.5   21113 0 0 1.5 2.5 7 31   31113 0 0 0 0 1 9.5 
11121 2 6.5 18.5 41.5 71.5 88.5   21121 0 0 3 13.5 50.5 82.5   31121 0 0 0 0 3 23.5 
11122 0 0 2.5 17.5 42 67   21122 0 0 1 6.5 28 58.5   31122 0 0 0 0 1.5 15 
11123 0 0 0.5 2 7 32   21123 0 0 0 1 5 27   31123 0 0 0 0 1 7 
11131 0.5 0.5 2 5.5 20 45.5   21131 0 0 0 0.5 8.5 34   31131 0 0 0 0 1 11.5 
11132 0 0 0 0.5 8.5 30   21132 0 0 0 0 5.5 23.5   31132 0 0 0 0 1 8 
11133 0 0 0 0.5 3.5 15.5   21133 0 0 0 0 1.5 11.5   31133 0 0 0 0 1 4 
11211 0 1 3 21 63.5 95.5   21211 0 0 0.5 8.5 42.5 89.5   31211 0 0 0 0 3 21.5 
11212 0 0 0 5.5 34 70.5   21212 0 0 0 4.5 24.5 64.5   31212 0 0 0 0 1.5 15 
11213 0 0 0 1 5.5 30   21213 0 0 0 1 3.5 26.5   31213 0 0 0 0 1 8 
11221 0 0 1 9 43.5 82.5   21221 0 0 0.5 4.5 33 76.5   31221 0 0 0 0 2 18 
11222 0 0 0 3.5 23.5 59.5   21222 0 0 0 2 15 51.5   31222 0 0 0 0 1 11.5 
11223 0 0 0 1 5 25.5   21223 0 0 0 1 3.5 20   31223 0 0 0 0 1 5 
11231 0 0 0 1.5 7 32.5   21231 0 0 0 0 3 26   31231 0 0 0 0 1 7.5 
11232 0 0 0 0 5 24.5   21232 0 0 0 0 2.5 18   31232 0 0 0 0 1 5.5 
11233 0 0 0 0 2 11   21233 0 0 0 0 1.5 8.5   31233 0 0 0 0 1 3.5 
11311 0 0 0 0.5 4 49   21311 0 0 0 0 2.5 38.5   31311 0 0 0 0 1 13 
11312 0 0 0 0 1 32.5   21312 0 0 0 0 1 25   31312 0 0 0 0 0.5 9 
11313 0 0 0 0 0.5 16.5   21313 0 0 0 0 0.5 13   31313 0 0 0 0 0.5 4.5 
11321 0 0 0 0 2.5 35   21321 0 0 0 0 2 28.5   31321 0 0 0 0 1 9.5 
11322 0 0 0 0 1 25.5   21322 0 0 0 0 1 16   31322 0 0 0 0 0.5 5 
11323 0 0 0 0 0.5 9   21323 0 0 0 0 0.5 7.5   31323 0 0 0 0 0.5 2.5 
11331 0 0 0 0 1.5 15.5   21331 0 0 0 0 1 10.5   31331 0 0 0 0 0.5 4 
11332 0 0 0 0 1 8.5   21332 0 0 0 0 1 5   31332 0 0 0 0 0.5 2 
11333 0 0 0 0 0.5 2.5   21333 0 0 0 0 0.5 2.5   31333 0 0 0 0 0.5 2 
12111 0.5 0.5 1.5 6.5 32.5 83.5   22111 0 0 0.5 3 22 74   32111 0 0 0 0 2.5 20 
12112 0.5 0.5 1 3 20.5 61.5   22112 0 0 0 1 13 54.5   32112 0 0 0 0 2 13 
12113 0.5 0.5 0.5 1 5 26.5   22113 0 0 0 0 1.5 21   32113 0 0 0 0 1 7 
12121 0 0 0.5 2.5 23 69.5   22121 0 0 0.5 1.5 16.5 62.5   32121 0 0 0 0 2 16.5 
12122 0 0 0.5 1.5 13.5 48.5   22122 0 0 0 0 8.5 40   32122 0 0 0 0 1.5 10 
12123 0 0 0 0 2.5 19   22123 0 0 0 0 1.5 15.5   32123 0 0 0 0 1 6 
12131 0 0 0 0 5.5 29.5   22131 0 0 0 0 4 26.5   32131 0 0 0 0 1 8.5 
12132 0 0 0 0 2.5 22   22132 0 0 0 0 2 17   32132 0 0 0 0 1 5.5 
12133 0 0 0 0 1 10   22133 0 0 0 0 1 8.5   32133 0 0 0 0 1 4 
12211 0 0 0.5 2 23 73.5   22211 0 0 0.5 1.5 13.5 68   32211 0 0 0 0 2 16 
12212 0 0 0 1 14.5 54.5   22212 0 0 0 0.5 7.5 44.5   32212 0 0 0 0 1.5 10 
12213 0 0 0 0 2.5 20   22213 0 0 0 0 1.5 15.5   32213 0 0 0 0 1 6.5 
12221 0 0 0.5 1.5 15 61   22221 0 0 0.5 1 9 54.5   32221 0 0 0 0 1.5 11 
12222 0 0 0 0.5 8 41.5   22222 0 0 0 0 4 33.5   32222 0 0 0 0 1 5.5 
12223 0 0 0 0 2 15.5   22223 0 0 0 0 1.5 11   32223 0 0 0 0 1 4.5 
12231 0 0 0 0 2 22.5   22231 0 0 0 0 1.5 19.5   32231 0 0 0 0 1 6 
12232 0 0 0 0 1 15.5   22232 0 0 0 0 1 12.5   32232 0 0 0 0 1 4 
12233 0 0 0 0 1 7   22233 0 0 0 0 1 6.5   32233 0 0 0 0 1 3.5 
12311 0 0 0 0 1 35.5   22311 0 0 0 0 1 26.5   32311 0 0 0 0 1 10 
12312 0 0 0 0 0.5 22.5   22312 0 0 0 0 0.5 15   32312 0 0 0 0 0.5 6.5 
12313 0 0 0 0 0.5 10   22313 0 0 0 0 0.5 7   32313 0 0 0 0 0.5 4 
12321 0 0 0 0 1 24   22321 0 0 0 0 1 17.5   32321 0 0 0 0 1 6.5 
12322 0 0 0 0 0.5 15   22322 0 0 0 0 0.5 8.5   32322 0 0 0 0 0.5 3.5 
12323 0 0 0 0 0.5 5   22323 0 0 0 0 0.5 4   32323 0 0 0 0 0.5 2.5 
12331 0 0 0 0 0.5 9   22331 0 0 0 0 0.5 7   32331 0 0 0 0 0.5 3 
12332 0 0 0 0 0.5 4   22332 0 0 0 0 0.5 2.5   32332 0 0 0 0 0.5 2 
12333 0 0 0 0 0.5 2   22333 0 0 0 0 0.5 2   32333 0 0 0 0 0.5 2 
13111 0 0 0.5 0.5 3 32   23111 0 0 0 0 1 21   33111 0 0 0 0 0.5 11 
13112 0 0 0 0 1.5 20   23112 0 0 0 0 1 16   33112 0 0 0 0 0.5 8.5 
13113 0 0 0 0 0.5 9.5   23113 0 0 0 0 0.5 9   33113 0 0 0 0 0 5 
13121 0 0 0 0 1.5 21   23121 0 0 0 0 1 18   33121 0 0 0 0 0.5 10.5 
13122 0 0 0 0 1.5 15   23122 0 0 0 0 1 12.5   33122 0 0 0 0 0 6 
13123 0 0 0 0 0.5 8   23123 0 0 0 0 0.5 7.5   33123 0 0 0 0 0 4 
13131 0 0 0 0 1 11   23131 0 0 0 0 0.5 9   33131 0 0 0 0 0 5 
13132 0 0 0 0 1 7.5   23132 0 0 0 0 0.5 6.5   33132 0 0 0 0 0 3.5 
13133 0 0 0 0 0.5 5   23133 0 0 0 0 0.5 4.5   33133 0 0 0 0 0 2 
13211 0 0 0 0 0.5 20   23211 0 0 0 0 0.5 15   33211 0 0 0 0 0.5 7 
13212 0 0 0 0 0.5 14.5   23212 0 0 0 0 0.5 10.5   33212 0 0 0 0 0.5 4.5 
13213 0 0 0 0 0.5 8.5   23213 0 0 0 0 0.5 7   33213 0 0 0 0 0 4 
13221 0 0 0 0 0.5 16.5   23221 0 0 0 0 0.5 12   33221 0 0 0 0 0.5 6 
13222 0 0 0 0 0.5 10.5   23222 0 0 0 0 0.5 8   33222 0 0 0 0 0 3 
13223 0 0 0 0 0.5 6   23223 0 0 0 0 0.5 5   33223 0 0 0 0 0 2.5 
13231 0 0 0 0 0.5 8   23231 0 0 0 0 0.5 7   33231 0 0 0 0 0 3 
13232 0 0 0 0 0.5 4.5   23232 0 0 0 0 0.5 4   33232 0 0 0 0 0 1.5 
13233 0 0 0 0 0.5 4   23233 0 0 0 0 0.5 3.5   33233 0 0 0 0 0 1.5 
13311 0 0 0 0 0.5 13   23311 0 0 0 0 0.5 8.5   33311 0 0 0 0 0 5.5 
13312 0 0 0 0 0.5 7.5   23312 0 0 0 0 0.5 5   33312 0 0 0 0 0 3.5 
13313 0 0 0 0 0.5 5.5   23313 0 0 0 0 0.5 4   33313 0 0 0 0 0 2.5 
13321 0 0 0 0 0.5 9   23321 0 0 0 0 0.5 6   33321 0 0 0 0 0 3 
13322 0 0 0 0 0.5 5   23322 0 0 0 0 0.5 3   33322 0 0 0 0 0 1.5 
13323 0 0 0 0 0.5 3   23323 0 0 0 0 0.5 2.5   33323 0 0 0 0 0 1 
13331 0 0 0 0 0.5 4   23331 0 0 0 0 0.5 3   33331 0 0 0 0 0 1.5 
13332 0 0 0 0 0.5 1.5   23332 0 0 0 0 0.5 1   33332 0 0 0 0 0 0.5 
13333 0 0 0 0 0.5 1   23333 0 0 0 0 0.5 1   33333 0 0 0 0 0 0.5 
The data represent the % of respondents who consider the health profiles acceptable 
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IV.4.10. The association of the acceptability and utility of health states 
We also examined, how the acceptability of certain health profiles was associated with 
their utility levels. Because the EQ-5D-3L questionnaire does not have a Hungarian 
value set, we used in our calculations the index values of the UK-TTO value (Dolan, 
1997) set, which is most frequently applied in Hungary in health economic analyses.  
We depicted the EQ-5D-3L index values of the 243 EQ-5D-3L profiles, as well as the 
probability of their acceptability in the 80-year-old age group (Figure 28, left graph). 
The association was not linear, the shape of the scatterplot showed a break at 
approximately 0.2 EQ-5D-3L index values. The acceptability of the profiles below 
0.2 EQ-5D-3L index was low, and it depended only a small amount on the change of 
the utility values. However, above 0.2 EQ-5D-3L index values, the acceptability and 
utility scatterplot suggested a strong linear association.   
We found a similar break when comparing the UK-TTO value set and the Polish TTO 
value set, in the proximity of 0.2 EQ-5D-3L index values. In the Polish value set, 
index values of 0.2 in the UK-TTO value set corresponded to values around 0.5, 
suggesting that in this range the Polish population rated less severe (and probably 
more acceptable?) than British respondents.  
Figure 28 Comparison of the acceptability and utility of EQ-5D profiles 
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Left figure: EQ-5D-3L index values and acceptability of 243 EQ-5D-3L profiles from 80 years of age. 
Right figure: comparison of EQ-5D-3L index values calculated with the UK-TTO and Polish-TTO 
value sets, for the 243 EQ-5D-3L profiles. UK-TTO: British time-trade-off value set, Polish TTO: 
Polish time-trade-off value set 
 
 
During the separate evaluation we found that the acceptability of health problems was 
associated not only with their severity or the age, but also with the dimension the 
problems were reported in (Table 4.) We wondered, how the results of joint evaluation 
are affected by the dimensions in which the health problems are reported. We tested 
the question with a logistic regression model, in which the dependent variable was the 
acceptability of the EQ-5D-3L profile (yes-no), and as predictors, we entered dummy 
variables for: age, severity of the profile (misery index), and the occurrence of any 
problems in the EQ-5D dimensions. We clustered the robust standard errors at the 
levels of the individuals (Table 8). Greater coefficients represented a greater 
acceptability of profiles. The explanatory power of the model was good (pseudo-
R2=0.476). Although the Hosmer- Lemeshow test was significant (c2(8)=313,19, 
p<0,0001), which suggests problems with the model fit, in the acceptability range 
above 0.5% the model fit was good. According to our expectations, in the older age 
group the acceptability was greater, and it was smaller in case of more severe 
problems. We compared the problems in different EQ-5D dimensions with the Wald 
test. The coefficient of self-care problems was significantly smaller than that of any 
other dimensions, while the pairwise comparison of all other dimensions showed not 
significant difference. According to the results, in the same age, a health state with the 
same severity is less likely to be acceptable, if it is characterised by problems in the 
self-care dimension. Although the evaluation of health-state utilities is based on 
finding detailed nuances in  the differences between people’s preferences about each 
dimension, by analysing the acceptability of health states, we did not find such 
differences between the effect of EQ-5D dimensions on acceptability, with the 
exception of the self-care dimension.  
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Table 8 The influence of health dimensions on the acceptability of health states 
Logistic regression  Log-OR (se) 
Age (years) 40 0.66*** (0.15) 
 50 1.74*** (0.20) 
 60 3.01*** (0.25) 
 70 4.81*** (0.28) 
 80 6.90*** (0.27) 
Severity (misery index) 6 -2.69*** (0.11) 
 7 -4.62*** (0.21) 
 8 -6.18*** (0.31) 
 9 -7.53*** (0.43) 
 10 -8.69*** (0.56) 
 11 -9.66*** (0.69) 
 12 -10.5*** (0.80) 
 13 -11.3*** (0.91) 
 14 -12.3*** (1.21) 
 15 -2.69*** (0.11) 
Dimension Mobility 1.12*** (0.11) 
 Self-care 0.65*** (0.099) 
 Usual activities 1.09*** (0.12) 
 Pain/discomfort 1.21*** (0.12) 
 Anxiety/depression 1.05*** (0.12) 
Constant  -5.13*** (0.29) 
 N 290400  
Robust standard errors were clustered at the individual level 
* p < 0.05, ** p < 0.01, *** p < 0.001 
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IV.4.11. The effect of response time on the reliability of AH measurements  
Response times of AH evaluation showed considerable variability. We wondered, 
whether the time spent with answering the questions influences the results of 
evaluation? During joint evaluation, the number of questions showed negative 
association with the average response time per question (r=-0,35, p<0,001). This may 
mean that respondents learned the evaluation task, but it may also be a signal of 
tiredness, increasingly superficial and hasty responses. We hypothesised that shorter 
response time than a certain limit is not enough for the appropriate evaluation of the 
acceptability of health states, and this may influence negatively the reliability of the 
measurement. We tested this question using a linear probability model, in which the 
acceptability of health states was estimated from the age and the severity of health 
states. In the model, fast responses were indicated by a dummy variable, for which the 
threshold was changed between 3 and 10 seconds. The main effects as well as the 
interaction of fast responses with age and severity was tested via a joint Wald test. 
Response times shorter than 8 seconds per question significantly affected the model 
coefficients. For response times shorter than 5 seconds, the main effects were 
significant, faster responses were associated with greater probability of accepting the 
problems, while the probability of accepting severe problems was lower. We did not 
store detailed data about the questions and their order asked during the joint 
evaluation, which could provide information about whether the quick answers were 
associated with the evaluation situation, the severity of displayed health states or their 
order (Table 9). However, randomly chosen thresholds around the mean response time 
(12-19 seconds) did not provide significant results in the model (Wald test p=0.1479) 
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Table 9 Evaluation of response time effects via linear probability model 
  Fast responses (sec) 
  <3sec <4sec <5sec <6sec <7sec <8sec <9sec <1sec 
Age 40 0.00065*** 0.00064*** 0.00065*** 0.00069*** 0.00073*** 0.00074*** 0.00070*** 0.00076*** 
 50 0.0031*** 0.0031*** 0.0031*** 0.0033*** 0.0034*** 0.0035*** 0.0036*** 0.0038*** 
 60 0.012*** 0.012*** 0.012*** 0.012*** 0.012*** 0.012*** 0.012*** 0.013*** 
 70 0.051*** 0.052*** 0.051*** 0.052*** 0.048*** 0.049*** 0.048*** 0.048*** 
 80 0.20*** 0.20*** 0.20*** 0.20*** 0.20*** 0.20*** 0.20*** 0.20*** 
Severity 6 -0.66*** -0.66*** -0.66*** -0.66*** -0.65*** -0.65*** -0.65*** -0.64*** 
(misery index) 7 -0.83*** -0.83*** -0.83*** -0.83*** -0.83*** -0.83*** -0.83*** -0.83*** 
 8 -0.91*** -0.91*** -0.91*** -0.91*** -0.91*** -0.91*** -0.91*** -0.91*** 
 9 -0.96*** -0.96*** -0.95*** -0.96*** -0.96*** -0.96*** -0.96*** -0.96*** 
 10 -0.98*** -0.98*** -0.98*** -0.98*** -0.98*** -0.98*** -0.98*** -0.98*** 
 11 -0.99*** -0.99*** -0.99*** -0.99*** -0.99*** -0.99*** -0.99*** -0.99*** 
 12 -0.99*** -0.99*** -0.99*** -0.99*** -0.99*** -0.99*** -1.00*** -0.99*** 
 13 -1.00*** -1.00*** -1.00*** -1.00*** -1.00*** -1.00*** -1.00*** -1.00*** 
 14 -1.00*** -1.00*** -1.00*** -1.00*** -1.00*** -1.00*** -1.00*** -1.00*** 
 15 -1.00*** -1.00*** -1.00*** -1.00*** -1.00*** -1.00*** -1.00 -1.00*** 
Fast response Yes 0.014* 0.020*** 0.017** 0.010 0.0053 0.0050 0.0011 0.0037 
x Agera 40 -0.00024 -0.000056 -0.00017 -0.00036 -0.00049* -0.00053* -0.00025 -0.00040 
 50 0.0014 0.00040 0.00026 -0.00098 -0.0016 -0.0018* -0.0018* -0.0022** 
 60 -0.0061** -0.0068** -0.0013 -0.0044 -0.0039 -0.0047 -0.0030 -0.0033 
 70 -0.013 -0.022* -0.014 -0.013 0.011 0.0074 0.011 0.0060 
 80 -0.068* -0.089*** -0.087*** -0.043 -0.037 -0.030 -0.013 -0.022 
x Severityb 6 0.055 -0.0032 0.0087 -0.020 -0.033 -0.037 -0.043 -0.052* 
(misery index) 7 0.012 -0.020 -0.0034 -0.0029 -0.0092 -0.012 -0.015 -0.019 
 8 -0.017 -0.032* -0.025* -0.013 -0.016 -0.016 -0.012 -0.013 
 9 -0.021** -0.027*** -0.026*** -0.015 -0.011 -0.010 -0.0051 -0.0074 
 10 -0.015** -0.017*** -0.017*** -0.010 -0.0028 -0.0017 0.0026 -0.00071 
 11 -0.0095** -0.011*** -0.011*** -0.0064 0.0024 0.0029 0.0071 0.0037 
 12 -0.0066** -0.0069** -0.0071** -0.0048 0.0043 0.0042 0.0083 0.0055 
 13 -0.0044* -0.0045* -0.0046* -0.0038 0.0042 0.0039 0.0078 0.0057 
 14 -0.0026 -0.0026 -0.0027 -0.0028 0.0029 0.0025 0.0063 0.0049 
 15 -0.00091 -0.00093 -0.00095 -0.00099 -0.0011 -0.0011 0.0036 0.0029 
Constant  0.96*** 0.96*** 0.96*** 0.96*** 0.96*** 0.96*** 0.96*** 0.96*** 
 N 281394 281394 281394 281394 281394 281394 281394 281394 
Wald-test p <0.0001 <0.0001 0.0002 0.1479 0.0112 0.0070 0.0577 0.1358 
IV.5. Discussion 
The first part of the dissertation introduced the methodological background and main 
results of two new measurement methods of AH: joint evaluation and acceptable 
VAS.  
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The newly developed adaptive testing algorithm for joint evaluation was feasible in 
practice, and after the separate evaluation task, it provided a more accurate picture on 
acceptable health, than separate evaluation.  
a) Separate and joint evaluation was feasible within on average 6-7 minutes per 
respondent 
b) Although the efficiency of the adaptive testing algorithm fell below the 
expected range, instead of 90% of respondents, we could elicit the 
acceptability of all elements of the E-matrix only for 43.5% of respondents 
(H1). However, only 2.3% of all health states remained unknown.  
c) During joint evaluation respondents accepted fewer problems than in separate 
evaluation (H2). The aggregated health curve from the results of joint 
evaluation (AHCjoint) fell between the values of the acceptable health curves 
gained after separate evaluation (AHCaggregate, AHCworst), and the smaller 
dispersion of AHCjoint than that of AHCaggregate enabled a more accurate 
measurement.  
d) Measuring AH with the EQ VAS also demonstrated that people in older ages 
consider more health problems acceptable than in younger ages (H3).  
The results confirmed the conclusions of previous studies, that there is a reference 
point of acceptable health, based on which people can evaluate, whether certain health 
states are acceptable in different ages or not (Brouwer et al., 2005, Pentek et al., 2014b, 
Wouters et al., 2015). Our research confirms previous results, according to which:  
a) people accept more health problems with age 
b) moderate problems are more acceptable than severe ones 
c) the acceptability of problems depends on the type of problem 
The first step of joint evaluation is separate evaluation, in which we received strikingly 
similar results to previous studies, which confirms the validity of the AH concept.  
Healthy respondents from another country (Wouters et al., 2015) and chronic patients 
from Hungary (Pentek et al., 2014b) evaluated acceptable health in a suprisingly 
similar way. The comparison of acceptable problems reflected previous experiences 
with the measurement of health outcomes. Patients accomodate the deterioration of 
their condition, therefore they attach higher utilities to health problems, than healthy 
individuals (Brazier et al., 2018, Ubel et al., 2003). This was reflected by the opinion 
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of rheumatoid arthritis patiens affected by a painful and destructive inflammatory 
condition of joints mainly in hands (Smolen et al., 2017), who, in the dimensions of 
self-care, usual activities and pain / discomfort considered health problems more 
acceptable than the general population. However, in acceptability of problems in the 
mobility dimension we found no differences between patients and the participants of 
our study, despite the fact that there are market differences between the occurrence of 
problems in this dimension between patients and the normal population (Pentek, 
2007). The dutch population considered problems in the anxiety / depression 
dimension less acceptable than respondents of the Hungarian sample, which reflects 
the Dutch preferences in EQ-5D-3L valuation studies. Compared to other countries, 
the Dutch assign greatest disutility to problems experienced in the dimension of 
anxiety / depression (Szende et al., 2006). Interestingly, pain/discomfort is evaluated 
similarly negatively to anxiety/depression by the Dutch, but in this field their 
preferences are similar to other countries’, which may explain why acceptability in 
the pain/discomfort dimension did not differ compared to the Hungarian population. 
In our own research predominantly problems in the self-care dimension influenced 
the acceptablilty of health states. By our respondents problems were experienced least 
frequently in this dimension, and when comparing to the normal population, the 
difference in the frequency of problems was greatest in in the self-care dimension. 
Based on these results, it is intrigueing, how certain kinds of health-related 
experiences, and more narrowly the frequency of problems experienced by oneself or 
others influence the opinion of individuals about the acceptability of health states.  
The acceptability of health states is presumably influenced (at least partly) differently 
by the preferences of the individuals, than the valuation of health state utilities. The 
evaluation of AH differs in many regards from the valuation of health utilities. The 
valuation of AH is not related so closely with assumptions about death and expected 
life-span, than the valuation of utilities. Also, there is no hypothetical exchange in the 
evaluation task, and there is no need to estimate probabilities of events (Brazier et al., 
2018, Parkin and Devlin, 2006). Therefore, the criteria of the expected utility theory 
do not hold (van Osch et al., 2004, Bleichrodt and Johannesson, 1997). Alghough we 
do not understand exaclty the cognivite processes underlying the evaluation of AH, 
we may assume that those are different from the ones underlying the elicitation of 
utilities.  
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During the valuation of utilities respondents need to imagine themselves in health 
states that span long periods of time. A central question of the debates about the 
methodology of QALY measurement is how valid this situation is, and whether the 
respondents momentary state or the opinion of patients who previously experienced 
problems had is a more authentic foundation for the elicitation of health state utilities 
(Brazier et al., 2018). The evaluation of AH requires a new hypothetical situation: the 
acceptability of different health states needs to be imagined in different ages. This, 
depending on the age and attitude of respondents may be influenced by a mixture of 
their current and past experiences, as well as their imagination about the future, their 
own health, and their health-related experiences in their environment. Acceptable 
health was evaluated significantly differently by those, who imagined themselves or 
others during the joint evaluation task. Similar differences were found in EQ-5D 
valuation studies eliciting health state utilities (Mulhern et al., 2013). The individuals 
health status, lifestyle, the life span of close relatives and informal caregiver status all 
influenced the evaluation of acceptable health. The dispersion of AHCjoint and the 
self-rated EQ-5D-3L index values suggested that in older age groups respondents 
form a more inhomogenous picture about acceptable health problems, than in younger 
ages. Since the goal of AH measurement is the reflection of societal preferences, it is 
important to elicit the general opinion of individuals. Therefore, building on the 
learnings from past research, an important aspect of future studies of acceptable health 
may be the as accurate as possible description of the evaluation task while not losing 
the merits of its relative simplicity:   
a) What do we mean exactly under acceptable health?  (Health states without 
losing wellbeing, or still bearable suffering?) 
b) Whose health should be imagined by the respondent. (Himself/herself in 
different ages, or his/her environment, average or extreme examples?) 
c) From whose point of view should respondents evaluate the acceptability of 
problems. (Their own opinion, or what do people generally consider 
acceptable?) 
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We have experienced all above interpretations of our respondents during the 
fieldwork.  
We have discovered a breakpoint in the association between the utility and 
acceptability of health states in the proximity of EQ-5D-3L index values of 0.2. We 
have found a break in a similar position in the association between the Polish and 
British utility values, which were elicited with the very same methodology. Therefore, 
the question emerges, to what extent the differences between the acceptability and 
utility of EQ-5D-3L profiles are explained by the differences of the two methods, or 
the differences between the health-related preferences of Easter-European or British 
populations. One of the key proceeds of the large number of EQ-5D valuation studies 
is that they highlight the importance of the differences between country value sets 
explained by methodological differences between the studies (Brooks et al., 2003, 
Augustovski et al., 2013, Bernert et al., 2009, Xie et al., 2014). The the benefit of 
measuring AH lies exactly in its major difference from the health state utilities. The 
lower the association between AH and utilities, the more adequate it may be for the 
authentic representation of the society’s preferences related to age and the severity of 
disease in a multiple-criteria decision setting (Marsh et al., 2016, Thokala et al., 2016).  
An important aspect of evaluating AH is checking the reliability of the adaptive testing 
algorithm. Adaptive testing was based on three assumptions, which are logical and 
seem to be plausible, but have not yet been empirically proven:  
a) The monotonicity of health states: if a health state is acceptable, then a less 
severe health state (same level or lower level of problems in any dimension) 
is also acceptable and vice versa.  
b) The monotonicity of health deterioration: if a health state is acceptable in a 
certain age, then it is acceptable in older ages and vice versa.  
c) Respondents provide reliable answers that are consistent with their priorities.  
During our research, unanswered questions emerged concerning all three points 
above. The first point is contradicted by seemingly illogical health states: let’s imagine 
a health state in which the individual is bedridden, without problems in usual activities 
and self-care. When evaluating acceptability, respondents may mix what they consider 
acceptable and what possible.  
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Concerning the second point, the anxiety / depression dimension can be mentioned as 
an example. In our research, we met respondents, who considered anxiety / depression 
acceptable in younger ages (most frequently mentioning work and family-related 
reasons), but with the advancement of age, they would consider the attenuation of 
anxiety / depression symptoms acceptable.  
Regarding the third point we have only indirect information from our research. During 
the joint evaluation we provided the opportunity for our respondents to change their 
responses of separate evaluation. This happened in case of 12 respondents from the 
200, two respondents changed their opinions twice during the joint evaluation task. 
One may wonder, what was reflected in their first or second opinion, or how reliable 
were the responses of those, who completed the evaluation task within the shortest 
time? In EQ-5D valuation studies, due to inconsistent responses, up to one third of 
respondents are excluded. Milder inconsistencies are accepted, but there were 
respondents, who valued full health (11111) worse than the worst EQ-5D profile 
(33333) (Brooks et al., 2003). Our adaptive testing algorithm on one hand protects us 
from logical inconsistencies, because it automatically fills logically consistent 
answers. But exactly this feature poses a risk concerning the reliability of the results. 
The algorithm provides consistency in case of not well-thought-through answers, and 
it amplifies the effect of random responses. The inclusion of control-questions, and 
the determination of the acceptable level of inconsistency is an important development 
task. Another problem is that due to the random sequence of questions starting from 
the extremely heterogenous AHCaggregate patterns, the individual properties of 
questions, and their influence on response patterns is very difficult to study. The 
analysis of the time spent with answering the questions has highlighted this problem: 
from the mechanism of the algorithm, it cannot be excluded, that two subjects receive 
the following randomly selected questions:  
a) 33233 in 70 years of age, 11221 in 50 years of age, 33212 in 70 years of age, 
12121 in 50 years of age, and so on.  
b) 31211 in 60 years of age, 23121 in 60 years of age, 22131 in 60 years of age, 
23212 in 60 years of age, and so on. 
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In the first case, we may assume that the contrast between the questions leads 
respondents to make faster decisions, while in the second case, the precise 
interpretation and imagination of the highly similar states may take more time 
Although responses shorter than 5-8 seconds influenced significantly the results of 
evaluation, they could be either positive (confident respondent, easily decidable 
question) or negative (tiredness, boredom) quality signals, which cannot be controlled 
according to the current mechanism of the adaptive testing algorithm. The above 
considerations reinforce the need for amending the joint evaluation module with 
elements that improve the reliability of the adaptive testing strategy.  
In addition to measuring AH by joint evaluation of discrete health states, using the 
modified EQ VAS was also a novelty of our research. The goal of EQ-5D profiles is 
to provide cardinal values for public decision-making, that reflect the preferences of 
the general population, and which make individuals or diseases comparable between 
each other (d'Aspremont and Gevers, 2002).   During the evaluation of discrete khealth 
states, several acceptable health states may occur in the same age, from which when 
we construct the AHCjoint, we use the lowest utility values that were determined by 
not reflecting the preferences of the individual in questions, but those of the general 
society. Therefore the applied utilities may differ from those of the individual in 
question. However, the EQ VAS provides a single numerical value about the current 
state of the individual, which can be influenced by health factors, which fall outside 
the dimensions of EQ-5D (Feng et al., 2014). On the other hand, the EQ VAS does 
nor provide information about based on what objective criteria do individuals compare 
the acceptability of health states with their inner reference image during the evaluation 
task. It merely informs about where AH falls between the best and worst imaginable 
health states. Alghough the raison d’etre of EQ VAS in the valuation of health has 
been criticised due to its incompatibility with the expected utility theory, due to its 
psychometric properties, for the measurement of societal preferences that are not 
measurable in monetary terms, we can accept the EQ VAS as a suitable instrument. 
(Parkin and Devlin, 2006) The differences between the courses of the AHCvas and 
AHCjoint curves between the ages 40 and 60 suggests that such problems may 
influence the evaluation of AH, which are not reflected in the EQ-5D dimensions 
(sleep, sensory problems, cognition or sexual life) (Brazier et al., 2019, Brouwer et 
al., 2005), which are indirectly arguments in favour of extending the dimensions used 
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for the elicitation of QALYs. AH may be a feasible concept for understanding the 
acceptability of health states other than EQ-5D profiles, and thereby it may be used as 
a more patient-centric tool, or a tool that is capable of the elicitation of societal 
priorities concerning a broader concept of wellbeing (e.g informal care, capabilities).  
 
In addition to the elaboration of the strengths and limitations of our study, it has to be 
noted that the sampling of our research was not representative, therefore the reliability 
and generalisability of our results is limited.  
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V. THE ASSOCIATION OF ACCEPTABLE HEALTH AND HAPPINESS 
V.1. Background 
For the validity of the AH concept, a key assumption is that in acceptable health states 
further health improvement will increase the wellbeing of the individual to a lesser 
amount, than health gains in not acceptable health states (Wouters et al., 2017). If the 
individual’s wellbeing is closely related to health improvements even beyond the 
threshold of AH, then it raises ethical concerns against the application of the AH 
concept, from utilitarian point of view. However, if crossing the AH threshold is not 
associated with further wellbeing increases, then we can hypothesize that maximising 
health up to the acceptability threshold also maximises the wellbeing achievable in 
connection with health gains. In case we consider the treatment of everyone who is 
not in acceptable health, then it is in harmony with the egalitarian principle. Subjective 
wellbeing is a complex term, some theories use it synonymously with happiness 
(Veenhoven, 2012), while other theories view it as a complex construct containing 
affective (hedonist) and cognitive (eudaimonic) elements (Ryff and Keyes, 1995). In 
our research the relationship of wellbeing and AH was explored via the association of 
AH and scores on the 0-10 numeral happiness scale (Veenhoven, 2009, Veenhoven, 
1993). Since the measurement of AH according to our method happened from a 
societal perspective, it was concerned about the acceptability of health states by the 
society and not about to what extent our respondents considered their own health 
states acceptable. The priority of the individual versus societal viewpoint in QALY 
measurement is still a field of active debate among health economists (Brazier et al., 
2018). For the better understanding of AH, we felt important to examine it also from 
the individuals’ point of view: what factors influence whether individuals consider 
their own health acceptable or not? The application of the principle of AH can be fair 
if individual and societal priorities are in harmony, and those people are actually in 
acceptable health states, about whom the society assumes that.  
Therefore, we felt important to inquire whether the association between AH and 
subjective wellbeing (happiness) is concordant with the societal assumptions about 
the association between AH and happiness?  
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In our research the newly applied EQ VAS measured the level of AH in a single 
continuous variable, thereby enabling us the more delicate research of the individual 
factors that influence the acceptability of health problems. In the next sections of the 
dissertation we were looking for answers for the following questions:  
a) How does AH influence the individuals’ happiness reflecting the level of 
individual wellbeing? 
b) What factors influence whether individuals consider their own health 
acceptable?  
V.2. Methods 
V.2.1. Data 
In the previous chapters we measured the level of health that is considered acceptable 
by our respondents in different ages. However, in the examination of AH and 
happiness, the key question was whether respondents consider their own health 
acceptable or not. We intended to answer this question indirectly from the data 
available from our research, therefore we constructed two new variables and 
introduced two new terms.  
a) In the following we use the term relative health for the difference of the 
respondent’s own health and the level of health he/she evaluated as acceptable 
in his own age group (e.g. for a 35-44-year-old respondent at the age 40). So 
relative health theoretically a continuous variable that can take values between 
-100 and +100, which receives 0 value if the respondents’ own health and the 
health state considered acceptable in his/her age group receive the same score.  
b) Based on their relative health, we formed two groups from respondents: in the 
acceptable health group relative health was positive, respondents evaluated 
their own health better than the level they consider acceptable in their own age 
group. In the non-acceptable health group respondents had negative relative 
health values.  
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V.2.2. Statistical methods 
V.2.3. Exploring the relationship between AH and happiness 
Happiness is described by a 0-10 numeral scale, which can be analysed as a continuous 
ordinal or categorical variable. The World Happiness Report analyses happiness data 
by linear regression (Helliwell et al., 2018) therefore we chose multivariate regression 
of the analysis of the association between relative health and happiness, in which 
happiness was the dependent variable, and as explanatory variables we included age, 
subjective health, relative health as continuous variables, and further categorical 
variables concerning the demographic status, lifestyle and health problems. In 
addition to main effects we studied interactions as well, where we used the binary 
acceptable health variable instead of relative health. When comparing multiple 
models, we considered the explanatory power (R2 and adjusted R2), when interpreting 
model coefficients, we considered p<0.05 level of significance. Heteroskedasticity 
was interpreted visually based on the scatterplot of residuals and predicted values, 
collinearity of variables was checked based on the VIF value, and outliers were 
checked based on Cook’s D (>4/n), leverage (>2k+2/n), standardised residuals 
(absolute value >3), or standardised DfBeta (>2/Ön) criteria. Heteroscedasticity was 
also checked by the Breusch-Pagan test, model specification with the Ramsey-RESET 
test, and the distribution of standard residuals was checked with the Shapiro-Wilk test 
and the skewness-kurtosis test. We also checked the contribution of individual 
independent variables to the explanatory power of the model by Shapley-
decomposition.  
We used logistic regression of study to relationship between relative health and 
lifestyle. The dependent variable was the acceptable health binary variable, 
explanatory variables were age, gender, socio-demographic variables, health 
problems and the lifestyle of individuals. When interpreting model coefficients, we 
chose p<0.05 level of significance. We checked model fit with the Hosmer-Lemeshow 
test, and the discriminative power of the model was examined by the area under the 
ROC curve, optimal thresholds were calculated using the Youden-index (sensitivity + 
specificity-1).  
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V.2.4. Hypothesis testing 
The second goal was to explore the relationship between AH and happiness. The 
tested the three related hypotheses with the following methods:  
H4: In acceptable health status, the level of subjective health influences happiness to 
a smaller extent than in not acceptable health status.  We tested this hypothesis with 
the following multivariable regression model:  ℎ = 4 + 617 + 89:;7< + =17 ∗ 9:;7< + >7?9 + @7?9 ∗ 9:;7< + AB + C 
where h denotes happiness, a is the intercept, na denotes the binary variable of 
acceptable health with value of 1 if the individual is in not acceptable health status, 
and 0 if the individual has acceptable health status; eqvas is the individuals’ self-rated 
health score on the EQ VAS,  age is respondents’ age centred at 18 years and X is the 
vector of other explanatory variables. We evaluated H4 based on the parameter value 
of d:  
H0:  d=0 
Halt: d>0 
H4 can be accepted if H0 is rejected and Halt is accepted. (Results: p108) 
H5: Older individuals are more likely to consider their health acceptable than younger 
ones.  
H6: Individuals with more severe conditions consider their health less acceptable than 
healthier ones.  We tested H5 and H6 hypotheses using the following logistic 
regression model:  DE?FGHI = 4 + 67?9 + 89:;7< + =B + C 
where logitpA = log(pA/(1-pA)), pA is the probability that an individual considers his/her 
health state acceptable, age is the age of respondents centred at 18 years, eqvas is the 
self-rated current health of respondents measured on the EQ VAS scale.  We tested 
the H5 hypothesis based on the parameter value of b:   
H0:  b=0  
Halt:b>0 
H5 can be accepted if H0 is rejected and Halt is accepted.  (Results: p113) 
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We tested the H6 hypothesis based on the parameter value of g:   
H0:  g=0  
Halt: g>0 
H6 can be accepted if H0 is rejected and Halt is accepted.  (Results: p113) 
 
V.3. Results 
V.3.1. Descriptive statistics 
From the 200 respondents in case of 32 we did not have data about self-reported health 
or acceptable health data for the respondents’ age group, therefore they were excluded 
from the analysis. We conducted analyses on a sample of 168. The key characteristics 
of the sample are summarized below. Mean age was 45.67 years (SD: 15.99, range: 
25-93). In the 25-34, 35-44, 45-54, and 65+ age groups were 57 (33.9%), 29 (17.3%), 
15 (9.5%) and 24 (14.3%) respondents, respectively. 57.1% of respondents were 
female, 64.3% were married and 78% was employed, 63% had tertiary education. 
77.4% of the respondents came from households in the top two quintiles in terms of 
net income. Compared to the Hungarian normal population, the sample was younger, 
and was shifted towards higher education and higher income (KSH, 2011).  
Respondents rated on average 1.95 points (SD=13.732) lower their own health 
compared to the health they considered acceptable for their age. 88 respondents 
(52.4%) rated their own health as better, while 80 (47.6%) as worse than the 
acceptable level.  68.4% of the 24-35 year old age group belonged to the not 
acceptable group, while this decreased to 31% in the  45-54 year old group. In the 55-
64 year old group the percentage of not acceptable health was 50%, and it decreased 
to 29.2% among the 65+ group.  
58.9% of respondents were overweight, 20.8% were smokers, 10.1% were high risk 
drinkers and 58.9% did not exercise regularly. Their own health was rated on the EQ 
VAS scale 80.51 points from 100 (SD=14.514). Mean happiness was 7.26 points 
(SD=2.089). Respondents estimated their own expected life-span to 82 years 
(SD=10.383). The highest estimated life span was 120, the lowest 57 years. The life 
span of close relatives was shorter than 75 years in 35.7% of the cases. 32.1% of 
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respondents were an informal caregiver during the past 10 years, and 58.3% utilised 
some health care service.  
V.3.2. The association between relative health and happiness 
The coefficients and main statistical properties of the models are summarized in Table 
10. In a simple regression model relative health showed significant association with 
happiness (M1), which remained significant after controlling for age and gender (M2). 
The effect of socio-demographic variables was not significant, and they improved the 
explanatory power of the model only to a small extent (M3). Adding self-rated health 
(EQ Vas) increased substantially the explanatory power of the model (M4, R2=0.318), 
by adding to the model, the coefficients of relative health and age became non-
significant. From EQ-5D-3L dimensions problems in usual activities and anxiety / 
depression showed significant relationship with happiness (M5). Other variables 
related to health or lifestyle were not significant (M6), but two variables became 
significant in this model: pain showed mild positive, while high income mild negative 
association with the level of happiness. These two effects were contrary to our 
expectations. After removing non-significant variables, the effect of pain became non-
significant (M7). We tested the quality of M7 in detail. The scatterplot of the residuals 
and predicted values showed asymmetric distribution and outliers. Based on Cook’s 
D (>4/168=0,024), a leverage (>14/168=0,083), standardised residuals (absolute 
value >3), or standardised DfBeta (>2/Ö168=0,154) criteria and happiness values of 
0, we found 29 (17.3%) outliers. After removing them from the model, the parameters 
remained practically unchanged.   
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Table 10 Linear regression analysis of the relationship of happiness and AH  
 
 M1 M2 M3 M4 M5 M6 M7 
Relative health 0.028* 0.044** 0.046** 0.007 0.014 0.012 0.012 
Age (y)  -
0.042** 
-
0.040** 
-0.011 -0.014 -0.016 -0.013 
Female  0.286 0.215 0.230 0.172 0.079  
Married   0.274 0.415 0.450 0.462  
Employed   -0.799 -0.319 -0.139 -0.142  
Has diploma   -0.152 -0.04 0.115 0.023  
High income   -0.494 -0.708 -1.173 -0.912* -1.025** 
EQ VAS (0-100)    0.073** 0.045** 0.040** 0.044** 
Mobility     -0.684 -0.661  
Self-care     -0.839 -0.825  
Usual activities     -1.427** -1.424** -1.396** 
Pain / discomfort     0.890 0.931*  
Anxiety / depression     -1.584** -1.599** -1.326** 
Overweight      -0.409  
Smoking      -0.023  
High risk alcohol      -0.615  
Lack of exercise      -0.344  
Informal caregiver      -0.327  
Used health service       -0.049  
Intercept 7.311** 9.107** 9.566** 2.139 5.356** 6.036** 5.740** 
F 5.808 8.080 4.353 9.136 9.282 6.813 18.130 
p 0.017 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
R2 0.034 0.129 0.162 0.318 0.443 0.470 0.406 
Adjusted R2 0.028 0.113 0.125 0.283 0.395 0.401 0.384 
* p<0.05, ** p<0.01  
 
The Breusch-Pagan test (c2(df=1) = 7,53, p=0,0061) was significant, which suggested 
that the model was heteroscedastic. The Ramsey RESET test was also significant 
(F(3,156)=3,22, p=0,0244), which suggested model specification error, therefore the 
results were not reliable.  The residuals showed non-normal distribution based on the 
Shapiro-Wilk test (p=0.00092) and skewness-kurtosis test (pskewness=0.1398, 
pkurtosis=0.0012, joint test: c2(df=2)=11.01, p=0.004).  
Altogether, the diagnostics of M7 raised questions in several points about the model 
results, therefore we did not accept the model, and further examined the effect of 
relative health and age on the relationship of self-rated health and happiness, or in 
other words, whether being above or below the acceptability threshold in different 
ages modifies the relationship between happiness and self-rated health?  
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The next steps of the analysis are summarized in Table 11. Starting from M7, we 
changed relative health to the binary acceptable health variable, and for the more 
straightforward interpretation of results, we centred age to 18 years (M8). In the next 
step we examined the interaction of age and self-rated heatlh, which was not 
significant (M9). Then we examined the interaction between AH and self-rated health. 
The explanatory power of the model improved, and the interaction became significant, 
and the coefficients of self-rated health and AH have changed (M10). Interpretation 
of M10: if an individual has acceptable health status, then self-rated health does not 
influence the level of happiness. Based on the coefficients of the model, we could 
accept H4, since the d parameter denoting the interaction of subjective health and 
acceptable health in explaining happiness was significant and positive (p<0,05).  
However, after excluding outliers based on Cook’s D, leverage, dfbeta, and 
standardized residuals and extremes of happiness, the coefficients did not remain 
significant. The results were not significant even after excluding 3 cases with the 
highest leverage values. Therefore, H4 could not be accepted with certainty.   
The next question was whether in not acceptable health states, the relationship 
between happiness and self-rated health depends on age?  
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Table 11 The relationship between happiness, health and AH 
 M8 M9 M10 M11 M12 M13 
Not acceptable 0.033 0.026 -3.969*    
Not acceptable * Age    -0.124** -0.179** -0.142 
Age (centred to 18 y) -0.007 -0.23 -0.066 -0.010   
EQ VAS (0-100) 0.051** 0.044** -0.010 0.028  0.054** 
Age*EQ VAS  0.000 0.001 0.000   
Not acceptable*EQ VAS   0.049*    
Not acceptable* EQ VAS * Ager    0.002** 0.002** 0.002** 
High income -1.030** -1.018 -0.953** -0.948** -0.789*  
Usual activities -1.372** -1.335 -1.279* -1.264* -1.716**  
Anxiety / depression -1.299** -1.296 -1.271** -1.273** -1.446**  
Intercept 4.725** 5.210** 8.698** 6.482** 8.644** 2.973** 
F 17.803 15.196 14.63 15.146 22.156 27.487 
p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
R2 0.402 0.402 0.427 0.436 0.409 0.336 
Adjusted R2 0.379 0.376 0.398 0.407 0.391 0.324 
* p<0.05, ** p<0.01  
 
Therefore, we added to AH and the interaction of AH also their interaction with age 
in the model (M11). The interaction was significant, and the explanatory power of the 
model improved (R2=0.436). The interpretation of M11 is the following: in acceptable 
health self-rated health does not influence happiness, in not acceptable health states 
in case of young individuals self-rated health influences only to small extent, in older 
individuals to a greater extent the level of happiness. Shapley decomposition of the 
R2 of M11 suggested that AH-related interactions contributed to the explanatory 
power of the model by approximately 20%. M12 contained only the significant 
variables of M11. The explanatory power decreased only to a small extent (R2=0,409).  
Because usual activities and anxiety / depression are health-related problems, and 
income also has a strong influence on health (see Table 11 below), we replaced these 
variables with self-rated health in M13, which became significant. The interpretation 
of M13: in acceptable health the improvement of health affects happiness only to a 
moderate extent, while in not acceptable health the effect of self-rated health on 
happiness is the greater the older the individual is.  
The explanatory power of M13 (R2=0.336) was inferior compared to M12 (R2=0.409), 
which was compensated only to a small extent by the simplicity of the model. (M13 
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adjusted R2=0,324, M12 adjusted R2=0,391). Comparing with the World Happiness 
Report analysis focusing on the individual determinants of happiness (adjusted 
R2=0,237) (Helliwell et al., 2018), the explanatory power of models M12 and M13 
containing AH as an explanatory variable were good, M12 explained approximately 
40%, while M13 explained approximately 1/3 of the variance of happiness. The model 
was homoscedastic (Breusch-Pagan test: c2(df=2)=1,73, p=0,189), its specification was 
acceptable (Ramsey-RESET test: F(3,160)=0,34, p=0,7971), the distribution of standard 
residuals showed a mild skewness (Shapiro-Wilk test p=0,0011, skewness-kurtosis 
test: pskewness=0,0196, pkurtosis=0,0943, pjoint=0,0224). However, after the exclusion of 
outliers based on Cook’s D, leverage, DfBeta, standardised residuals and extreme 
values of happiness, only the effect of health remained significant. The effect of 
acceptable health did not remain significant even after the exclusion of the 3 
observations with the highest leverage values. After the exclusion of the three outliers, 
according to the Shapley-decomposition, the contribution of AH to the explanatory 
power of M11 decreased to 7%. Since we could exclude coding error during the data 
recording (electronic questionnaire), we need to accept data from the outliers as valid 
responses.  Therefore, we can assume that there are subgroups of respondents whose 
attitudes regarding health and happiness are rather heterogenous, which needs further 
exploration. Figure 29 illustrates the relationship between health and happiness based 
on the parameters of M12 and M13. We depicted the relationships in the EQ VAS 
ranges that were measured in the sample for the given subgroup.  
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Figure 29 The relationship of AH and happiness 
 
Left figure: based on the M12 parameters (Table 11) the graphical representation of the relationship 
between happiness and self-rated health (EQ VAS). In acceptable health (grey dashed line) the EQ 
VAS does not influence the individual’s happiness; however, anxiety/depression problems decrease it. 
In not acceptable health (coloured lines), the relationship between self-rated health and happiness is 
age-dependent. The older the individual, the steeper the lines are – the greater extent health influences 
the level of happiness. Right figure: based on the M13 parameters (Table 11) the graph shows the 
relationship between EQ VAS and happiness. The model is not controlled for specific health problems 
(anxiety/depression). In acceptable health (grey dashed line) health influences happiness to a smaller 
extent, while in not acceptable health (coloured lines) self-rated health influences happiness, to a 
greater extent in older ages.  
 
As a supplementary analysis we explored the relationship between income and the 
dimensions of health, since health related variables changed the magnitude and 
significance of the effect of income on happiness (M5). Table 12 summarizes the 
occurrence of health problems in a split according to income status. Among 
individuals in the lower income group every health problem (including usual activities 
and anxiety / depression) occurred more frequently.  
  
4
6
8
10
B
ol
do
gs
ág
40 60 80 100
EQ VAS
Elfogadható, szorong
Elfogadható, nem szorong
30 éves, nem elfogadható
50 éves, nem elfogadható
70 éves, nem elfogadható
M12
2
4
6
8
10
B
ol
do
gs
ág
40 60 80 100
EQ VAS
Elfogadható
30 éves, nem elfogadható
50 éves, nem elfogadható
70 éves, nem elfogadható
M13
H
ap
pi
ne
ss
 
H
ap
pi
ne
ss
 
Acceptable, anxi us 
Acceptable, not anxious 
30y old ot acceptable 
50y old, ot acceptable 
70y old, ot acceptable 
Acceptable 
30y old, ot acceptable 
50y old ot acceptable 
7 y old, ot acceptable 
 - 111 - 
Table 12 Occurrence of health problems in different income groups 
 
  Mobility Self-care Usual 
activities 
Pain / 
discomfort 
Anxiety / 
depression 
Any 
problems 
High 
income 
N (%) 16 (12.3%) 0 (0.0%) 6 (4.6%) 29 (22.3%) 33 (25.4%) 44 (33.8%) 
Expected N 24.9 1.6 13.2 38.9 40.5 54.4 
Low 
income 
N (%) 16 (43.2%) 2 (5.4%) 11 (29.7%) 21 (56.8%) 19 (51.4%) 26 (70.3%) 
Expected N 7.1 0.4 3.8 11.1 11.5 15.5 
Fischer’s exact p <0.001 0.048 <0.001 <0.001 0.004 <0.001 
Chi2(1) p <0.001 0.008 <0.001 <0.001 0.003 <0.001 
N=167, the table displays data from the cross-tabulation only for those, who indicated any problems in the dimensions 
 
We conducted Chi2 and Fischer’s exact tests on the cross-tabulation of data. The EQ 
VAS scores (skewness: -1.13, kurtosis: 2.0 Shapiro-Wilk test, p<0.001) were on 
average 8.9 points higher compared to individuals in the low-income group. The 
difference was significant. (Independent samples’ t-test: p=0.001 (equal variances: 
Levene-test p=0.220); Mann-Whitney U test: p=0.001). Interpretation of the 
parameters: the happiness of people in the high- and low-income groups does not 
differ significantly. This is explained by the greater frequency of health problems 
among the low-income group, which negatively influence happiness. In case of 
similar level of problems in usual activities or anxiety / depression, people in the low-
income group rated their happiness on average 1.025 points higher than the high-
income group. It is important to note that in a cross-tabulation, problems in the anxiety 
/ depression (chi2(1)=0.343, p=0.558) and usual activities (chi2(1)=0.215, p=0.643) 
dimensions did not show association with AH.  
 
V.3.3. The relationship between relative health and lifestyle 
The results of the logistic regression analysis (M14) are summarized in Table 13. The 
acceptability of the health status of respondents was influenced significantly by age, 
self-rated health, overweight and smoking status. Acceptable health status was 
denoted by the value of 1, while not acceptable health status was denoted by the value 
of 0. The interpretation of results is the following: the older individuals were or the 
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better their self-rated health was, the greater the chance was that they considered 
their own health state acceptable. Based on this result we could accept H5 and H6.  
Table 13 Factors influencing the probability of acceptable health 
Logistic regression M14 
Age (y) .083** 
EQ VAS .054* 
Female .393 
Married -.139 
Employed -.024 
Has diploma -.510 
High income -.065 
Overweight -1,491** 
Smoker  -1,311* 
High risk alcohol .680 
Lack of exercise -.546 
Expected life-span -.027 
Close relatives’ life span .052 
Informal caregiver -.517 
Healthcare use -.703 
Mobility problems .538 
Self-care problems .236 
Problems with usual activities .553 
Problems with pain / discomfort -.817 
Anxiety / depression .359 
Intercept 2.107* 
LR Chi2(20) 62.91 
p <0.001 
* p<0.05, ** p<0.01  
 
Holding all other parameters constant, smokers and overweight respondents had 
greater probability to evaluate their health status as not acceptable. The Hosmer-
Lemeshow test after splitting data to 10 deciles ((c2(df=8))=4.24, p=0.8346) was not 
significant, which suggests good model fit. The area under the ROC curve was 0.8377, 
so the discriminative power of the model was good. The logistic regression model 
provided accurate prediction in 75.6% of the cases, when using p=0.5 threshold value. 
The maximum of the Youden-index was at p=0.509. After setting the optimal 
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threshold, the proportion of accurate predictions improved only a small amount to 
76.2%.  
V.4. Discussion 
Acceptable health is an unexplored research field. This was the first study that applied 
EQ VAS for the measurement of AH. The first question was whether relative health 
is associated with the individual’s happiness? According to our analysis, happiness 
was determined by the self-rated health of individuals. Relative health influenced the 
association between health and happiness in an age-dependent manner. In case 
individuals considered their health better compared to the level considered acceptable 
in their age, health contributed to a smaller extent to their happiness, while in not 
acceptable health states health contributed happiness in increasingly with age. Based 
on these findings we could accept our H4, but the results were significantly affected 
by a small number of outliers in the sample, therefore it requires further analysis and 
repeated measurement in order to ascertain the validity of the finding described 
above.  
These results can support the positive thesis of the sufficientarian principle applied in 
health financing decisions, which aims to maximise the number of individuals in 
acceptable health. The maximisation of acceptable health corresponds with the 
maximisation of welfare, since individuals’ wellbeing is related to their health status 
unless they are not in acceptable health status (Wouters et al., 2017). According to our 
results, we need to pay more attention on the treatment of severe diseases in the older 
age group, and to the treatment of mental healht problems in anyage group and the 
restoration of usual activities, which influence the happiness, and thereby the 
subjective wellbeing of the individual to a great extent.  
According to our results, health influenced happiness differently than financial wealth. 
Through the status effect, the financial status relative to others, and not the absolute 
wealth is the determinant of happiness (Alderson and Katz-Gerro, 2016). However, 
Hungarian data have not supported this relationship, status effect and the hope 
generated by others financial growht as a positive information effect have cancelled 
out each others effects (Hajdu and Hajdu, 2011). In our own sample we demonstrated 
the the joint effect of self-rated health and the acceptable health on happiness. 
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However, our data were collected in a cross-sectional study, therefore we could not 
monitor the changes within individuals, only the differnces between individuals. We 
need to note that the level of AH showed great variability among individuals.  
The second part of our analysis was concerned with the relationship between AH and 
the lifestyle from the perspective of individual respondents. Higher age and better self-
rated health increased the chance that individuals rate their own health better than 
what they consider acceptable for their age. Based on these findings, we can accept 
our H5 and H6 hypotheses. Two important risk groups: overweight people and smokers 
indicated their health acceptable with a smaller probability than others, while 
problems in anxiety / depression and usual activities – which have strong impact on 
the happiness of individuals – did not influence the acceptability of health states.  
Implementing AH-based priority-setting would bring the following effects from the 
individuals’ perspective:  
a) According to the AH principle, the treatment of older individuals would 
receive lower priority. Since older individuals are more likely to consider their 
health acceptable, therefore their wellbeing would be affected to a lesser 
amount if their treatment would receive smaller priority. However, this is true 
only for mild health problems. The treatment of severe health problems 
contributes to the wellbeing of older individuals to a great extent.  
b) According to the AH principle, the treatment of severe conditions would 
receive higher priority. With the improvement of health, people are more 
likely to get into acceptable health states, therefore their treatment would 
influence their wellbeing favourably.  
c) Overweight people and smokers consider their health less acceptable than 
other in case of a similar health condition. According to the AH principle, 
similar treatment priorities would contribute to the welfare of those 
individuals, who can be partly held responsible for their health deterioration. 
This is also in harmony with certain societal priorities (Dolan et al., 2005, 
Gulácsi, 2012).  
d) However, mental problems would remain hidden from the eyes of decision-
makers: problems in the anxiety / depression dimension influence greatly the 
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happiness of individuals, while they are not associated with acceptable health 
from either the societal or the individuals’ perspectives.  
The propositions above are partly speculative, because important aspects of the 
evaluation of AH’s societal and individual consequences are not known. However, 
they highlight the importance, that acceptability should be rendered to the elements of 
the E-matrix from two directions:  
a) The societal perspective shows, to what extent people consider some health 
states acceptable 
a) The individual perspective shows, to what extent individuals consider their 
own health acceptable 
The question is what the relationship is between the two perspectives, and how the 
application of AH would influence the overall wellbeing of the entire society. AH 
represents two societal priorities in the allocation of resources: younger individuals 
should receive priority over older ones and sever conditions should receive priority 
over moderate ones. Application of the AH principle can lead to the maximisation of 
the wellbeing of the society, if the maximisation of acceptable health states according 
to societal priority weights corresponds to the maximisation of acceptable health states 
that are experienced by individuals.  
A key limitation of our research is that we measured acceptable health indirectly, we 
did ask respondents to evaluate the acceptability of their own health status directly. 
Furthermore, our cross-sectional sample did not show the fundamental intra-
individual relationships between AH and wellbeing, which is a key aspect of health 
technology assessment studies. Therefore, the associations described by our study 
have limited value in drawing conclusions about causal relationships. Furthermore, 
we examined the relationship of AH and wellbeing through the 0-10 numeral 
happiness scale, while some theories view wellbeing as a different broader concept 
than mere happiness (Ryff and Keyes, 1995). It is important to note, that sampling 
was not representative in our research therefore our results are not generalisable, and 
a small number of outliers influenced our results to a great extent. Therefore we 
suggest repeating our research in a greater representative sample.  
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VI. CONCLUSIONS 
In search of potential solutions for the sustainability challenges of healthcare 
financing, my PhD thesis summarizes the research about acceptable health - a new 
health measurement method reflecting societal priorities concerning age and disease 
severity - and its association with happiness.  
Based on the cross-sectional, non-representative study conducted in the Hungarian 
population, the following conclusions could be drawn:  
a) People consider health problems increasingly acceptable with age 
b) Mild health problems are more acceptable than more severe ones 
c) AH can be measured more precisely using the joint evaluation method, than 
with separate evaluation. Joint evaluation is feasible in practice and provides 
reasonably accurate measures about the acceptability of health states.   
d) EQ VAS is a convenient method to measure acceptable health  
e) Acceptable health from the individual’s perspective reflects similar priorities 
than from the society’s perspective.  
Before the adoption of the AH principle in real practice, the reliability of its method 
needs to be further developed. During joint evaluation we did not evaluate the 
consistency of responses, therefore the adaptive algorithm needs to be amended with 
self-control questions. Without control questions, random answers and answers 
reflecting real preferences cannot be separated.   
It is also important to clarify the concept of AH during the evaluation exercise in order 
to decrease potential errors arising from respondents’ misunderstanding or 
misinterpretation of the evaluation task.  
Furthermore, it is important to prove the basic assumption that in acceptable health 
status a unit health gain has lower utility (or smaller increase of wellbeing) than in not 
acceptable health status. Our findings concerning the association of AH and happiness 
are in line with this assumption. However, in our research acceptable health states 
were measured indirectly, and our results were influenced by a small number of 
outliers, therefore our measurement needs to be repeated on a sufficiently powered 
representative sample of the general population, by the direct evaluation of the 
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acceptability of individuals’ health status, as well as using more specific validated 
measures of health-related utility and subjective well-being.  
Finally, in addition to determining the E-matrix from the society’s perspective on AH, 
we consider important to measure the E-matrix from the individuals’ perspective as 
well, in order to verify the assumption that maximising health states that are 
considered acceptable from the society’s perspective simultaneously result in the 
maximisation of individual wellbeing.  
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